[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3319
1. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, Shirai T: Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):7-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model.
  • Since it was recently proposed as a potential prostate cancer chemopreventive agent, we here performed an in vivo experiment to explore its effect in the Transgenic Rat for Adenocarcinoma of Prostate (TRAP) model, featuring the rat probasin promoter/SV 40 T antigen.
  • Resveratrol suppressed prostate cancer growth and induction of apoptosis through androgen receptor (AR) down-regulation, without any sign of toxicity.
  • Resveratrol not only downregulated androgen receptor (AR) expression but also suppressed the androgen responsive glandular kallikrein 11 (Gk11), known to be an ortholog of the human prostate specific antigen (PSA), at the mRNA level.
  • The data provide a mechanistic basis for resveratrol chemopreventive efficacy against prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anticarcinogenic Agents / therapeutic use. Disease Models, Animal. Prostatic Neoplasms / drug therapy. Stilbenes / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439064.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Androgen Receptor Antagonists; 0 / Angiogenesis Inhibitors; 0 / Anticarcinogenic Agents; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Stilbenes; 0 / Ubiquitin; 0 / trypsin-like serine protease; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; EC 3.4.21.- / Serine Endopeptidases; Q369O8926L / resveratrol
  •  go-up   go-down


2. Vaidyanathan S, Soni BM, Mansour P, Hughes PL, Singh G, Oo T: Effect of spinal cord injury upon prostate: adenocarcinoma of prostate in a spinal cord injury patient - a case report. Cases J; 2009;2:9374

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of spinal cord injury upon prostate: adenocarcinoma of prostate in a spinal cord injury patient - a case report.
  • INTRODUCTION: Following spinal cord injury, prostate undergoes atrophy probably due to interruption of neuro-hormonal pathways.
  • The incidence of carcinoma of prostate is lower in patients with spinal cord injury above T-10 than in those with lesion below T-10.
  • In May 1995, routine blood test showed prostate-specific antigen to be 17.7 mg/ml.
  • Prostate biopsy revealed moderately differentiated primary adenocarcinoma of prostate; Gleason score was 3+3.
  • MRI of pelvis revealed no evidence of spread beyond prostatic capsule.
  • CONCLUSION: Although prostate gland undergoes atrophy in men who sustained spinal cord injury in early age, physicians should be vigilant and look for prostatic diseases particularly in men, who have sustained spinal cord injury during later period of life.
  • Therefore, it may be advisable to consider chemoprevention of prostate cancer with Finasteride, especially in men, who sustained cervical and upper dorsal spinal cord injury during later part of their life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2009 Aug;182(2):499-507; discussion 508 [19524966.001]
  • [Cites] Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S115-20 [19543430.001]
  • [Cites] Urology. 2009 May;73(5):935-9 [19328538.001]
  • [Cites] Scand J Urol Nephrol. 2007;41(2):120-3 [17454950.001]
  • [Cites] J Spinal Cord Med. 2001 Summer;24(2):92-4; discussion 95 [11587425.001]
  • [Cites] J Urol. 1997 Jan;157(1):195-8 [8976249.001]
  • [Cites] Arch Intern Med. 1995 Feb 27;155(4):389-92 [7531426.001]
  • [Cites] J Am Paraplegia Soc. 1994 Jul;17(3):148-9 [7964711.001]
  • [Cites] Spinal Cord. 2006 Jan;44(1):24-7 [16010271.001]
  • (PMID = 20062548.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2804017
  •  go-up   go-down


3. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • PURPOSE: The aim of the study was to analyze early effects and toxicity of salvage high dose rate brachytherapy for local recurrences of adenocarcinoma of the prostate after external beam radiotherapy (EBRT).
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


Advertisement
4. Mazeron JJ, Simon JM, Toubiana T, Lang P: [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate]. Bull Cancer; 2005 Dec;92(12):1078-84
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate].
  • [Transliterated title] Hormonoradiothérapie des adénocarcinomes non métastatiques de la prostate.
  • Non metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy.
  • Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormono therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396754.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


5. Chang F, Dávila S, Ovalles V, Mejías E, Rodríguez O, Rodríguez R: [Cervical adenopathy presentation of adenocarcinoma of prostate]. Actas Urol Esp; 2007 Nov-Dec;31(10):1193-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervical adenopathy presentation of adenocarcinoma of prostate].
  • [Transliterated title] Adenopatía cervical como presentación de adenocarcinoma de próstata.
  • The metastases of prostate cancer shows the regional lymphatic dissemination, being the cervical lymphatic metastases to infrequent and little reported in Literature.
  • When making biopsy of cervical adenopathy reported adenocarcinoma prostate metastases.
  • Within the diagnosis differential of the cervical adenopathys in neck in adult men it must consider the prostate carcinoma, because in an early diagnosis and adapting treatment it can prolong the survive.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18314662.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Menon S, Gujral S, Bakshi G, Tongaonkar HB: Bilateral testicular metastasis from prostatic adenocarcinoma mimicking an intertubular pattern of seminoma and expressing Rhamm. J Cancer Res Ther; 2010 Jan-Mar;6(1):97-9
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral testicular metastasis from prostatic adenocarcinoma mimicking an intertubular pattern of seminoma and expressing Rhamm.
  • Adenocarcinoma of prostate metastasizing to testis is a rare occurrence and is incidentally detected in orchiectomy specimens.
  • A rare case of bilateral testicular metastasis of prostatic adenocarcinoma is presented wherein the metastatic cells expressed CD168, a receptor for hyaluronan mediated motility (Rhamm), implicated in the development of androgen independence in prostate cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Antigens, CD44 / biosynthesis. Extracellular Matrix Proteins / biosynthesis. Prostatic Neoplasms / pathology. Seminoma / pathology. Testicular Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / secondary. Combined Modality Therapy. Diagnosis, Differential. Humans. Leuprolide / therapeutic use. Male. Middle Aged. Orchiectomy. Ultrasound, High-Intensity Focused, Transrectal

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479558.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antineoplastic Agents, Hormonal; 0 / Extracellular Matrix Proteins; 0 / hyaluronan-mediated motility receptor; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


7. de Paso Mora PG, Ríos BJ, Pascual Pareja FJ, Castillo Torres C, Pinto Marín A, Sendino Revuelta A, Vázquez RJ: Pleural effusion as presentation of metastatic adenocarcinoma of prostate. South Med J; 2005 Sep;98(9):959-60
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural effusion as presentation of metastatic adenocarcinoma of prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Pleural Effusion, Malignant / etiology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. L-Lactate Dehydrogenase / metabolism. Male. Prostate-Specific Antigen / blood. Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218001.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


8. Lopez S, Simon JM, Mazeron JJ: [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate]. Bull Cancer; 2009 Mar;96(3):261-70
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
  • [Transliterated title] Hormono-radiothérapie des adénocarcinomes non métastatiques de la prostate.
  • Non-metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy.
  • Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormone therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / radiotherapy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Gonadotropin-Releasing Hormone / analogs & derivatives. Humans. Male. Neoplasm Recurrence, Local / prevention & control. Prostate-Specific Antigen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318304.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 40
  •  go-up   go-down


9. Adams G, Mitchell A, Ravichandran R, Beer TM, Garzotto M: Metastatic adenocarcinoma of prostate in a healing sternotomy site. Urology; 2006 Jul;68(1):204.e13-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of prostate in a healing sternotomy site.
  • Metastatic prostate cancer has a strong predilection for osseous sites, where the disease spreads in 80% of advanced cases.
  • The molecular mechanisms involved in prostate cancer establishment in bone are largely unknown; however, local tissue factors, including those involved in wound healing, have been suggested to play a critical role.
  • We present a case of tumor explosion in a median sternotomy wound after local prostate cancer therapy.
  • This case highlights that novel therapeutic interventions that disrupt the apparent synergistic relationship between tumor cells and the pro-tumorigenic microenvironment may hold great promise in constraining the proliferation of prostate cancer metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Prostatic Neoplasms / pathology. Sternum / surgery. Wound Healing

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808964.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Osunkoya AO, Epstein JI: Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol; 2007 Sep;31(9):1323-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
  • Prostatic urothelial-type adenocarcinoma arises through a process of glandular metaplasia of the prostatic urethral urothelium and subsequent in situ adenocarcinoma sometimes associated with villous adenoma.
  • These prostatic adenocarcinomas are analogous to nonurachal adenocarcinomas arising in the bladder from cystitis glandularis.
  • Only 2 cases of urothelial-type adenocarcinoma from an institution other than our own have been previously described.
  • The distinction between adenocarcinoma from another organ secondarily involving the prostate, usual adenocarcinoma of the prostate, and prostatic urothelial-type adenocarcinoma can present a significant diagnostic challenge and has significant therapeutic implications.
  • Fifteen cases of prostatic urothelial-type adenocarcinoma were retrieved from the consult files of one of the authors.
  • Mean patient age at diagnosis was 72 years (range 58 to 93 y).
  • In 8/15 (53%) cases, glandular metaplasia of the prostatic urethra and contiguous transition to adenocarcinoma were identified.
  • Immunohistochemical stains were negative for prostate specific antigen, prostate specific acid phosphatase, CDX2, and beta-catenin in all cases.
  • Prostatic urothelial-type adenocarcinoma is a rare aggressive cancer arising in the prostate.
  • The differential diagnosis includes conventional prostatic mucinous adenocarcinoma and secondary infiltration from a colonic or bladder adenocarcinoma.
  • Immunohistochemistry for prostate specific antigen, prostate specific acid phosphatase, and high molecular weight cytokeratin along with morphology can help rule out conventional prostate carcinoma. beta-catenin, CDX2, and clinical studies are needed to rule out colonic adenocarcinoma.
  • As prostatic urothelial-type adenocarcinoma is entirely analogous to bladder adenocarcinoma in both, its morphology and immunophenotype, only clinical studies or in some cases pathologic examination of the cystoprostatectomy specimen can exclude infiltration from a primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Mucins / analysis. Prostatic Neoplasms / diagnosis. Urothelium / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Aged, 80 and over. Cell Differentiation. Diagnosis, Differential. Follow-Up Studies. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Time Factors. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721186.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucins; 0 / beta Catenin; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


11. Fleischmann AM, Waser B, Reubi JC: Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14575 Background: Tumoral Gastrin-releasing peptide (GRP) receptors are potential targets for diagnosis and therapy using radiolabeled or cytotoxic GRP analogs.
  • GRP-receptor overexpression has been detected in cancer cells and, more recently, also in the vascular bed of selected tumors.
  • More information on vascular GRP-receptors in cancer is required to asses their potential for vascular targeting applications.
  • METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the <sup>125</sup>I-[Tyr<sup>4</sup>]-bombesin radioligand and/or the universal radioligand <sup>125</sup>I-[D-Tyr<sup>6</sup>, ß-Ala<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]-bombesin(6-14).
  • RESULTS: Prevalence of vascular GRP-receptors is variable, ranging from 13% (prostate cancer) to 92% (urinary tract cancer).
  • Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).
  • Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb).
  • : e16119 Background: Id1, involved in cell differentiation, proliferation, tumor angiogenesis and metastasis, has recently showed to mediate lung MTS from breast cancer (PNAS 2007).
  • The expression of Id1 in human cancer has been related to poor prognosis breast, prostate (Gil-Bazo, Amer Soc Clin Oncol GU.
  • 2009) and other non-adenocarcinoma tumors.
  • CONCLUSIONS: For the first time using a MoAb against Id1 and in accord with our previous observations in prostate cancer the selection of PP pts increases tumor cell Id1 exp. from 28 up to 80%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Winkfield KM, Chen M, Dosoretz DE, Salenius SA, Katin MJ, Ross R, D'Amico AV: Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. J Clin Oncol; 2009 May 20;27(15_suppl):5068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
  • : 5068 Purpose: We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer.
  • METHODS: The study cohort was comprised of 4,880 men with clinical stage T1-3N0M0 prostate cancer and minimum follow-up of 2 years who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium.
  • CONCLUSIONS: African-American and Hispanic race as compared to white race appear to confer a higher risk of mortality following brachytherapy-based treatment in men with localized or locally advanced prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964249.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).
  • Forty-three pts received chemotherapy following the diagnosis of medullar infiltration, and normal leukocyte count was being seen in 40% of them after such treatment.
  • Nine episodes of febrile neutropenia were found; median overall survival (OS) following the diagnosis of neoplasia and myelophtisis were 13.8 months and 2.2 months respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Renzulli JF 2nd, Dooner G, Owens C, Colvin G, Dooner M, Del Tatto M, Goldstein L, Quesenberry P: Microvesicular-mediated gene transfer of prostate tumor markers. J Clin Oncol; 2009 May 20;27(15_suppl):e16076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvesicular-mediated gene transfer of prostate tumor markers.
  • Recent work has focused on the potential for cancer vaccines via microvesicles.
  • Our objective is to determine whether there is transfer of genetic or transcriptional factors via microvesicles from human prostate cancer cells to fresh human marrow cells.
  • METHODS: Fresh prostate tissue was harvested from surgical specimens following radical retropubic prostatectomy.
  • Samples were histologically confirmed to contain prostatic adenocarcinoma.
  • Co-cultures were established using a transwell system in which 0.05-0.100 grams of prostate tissue was minced and co-cultured with 1-3 million normal, human donor marrow cells for 2-7 days.
  • Target cells were collected and total RNA was analyzed for prostate-specific gene expression byReal Time RT-PCR.
  • RESULTS: We have observed significant increases in gene expression in marrow cells co-cultured with prostate tumor cells (Gleason grades 6-9).
  • CONCLUSIONS: These studies demonstrate that prostate specific genes are present in fresh human marrow cells after co-culture with tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963050.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Zhu Y, Chen L: Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22230

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells.
  • With an extensive understanding of their biology, a major role for stem cells in the malignant process has been proposed and the existence of cancer stem cells(CSCs) has been confirmed in hematopoietic malignancies, brain cancer, and solid organ malignancies including breast, prostate, colon, and pancreatic cancer.
  • Lung cancer is the leading cause of cancer mortality in most large cities of China.
  • It is possible that lung cancer contains cancer stem cells responsible for its malignancy.
  • The aim of this study is to identify, characterize and enrich the CSC population that drives and maintains lung adenocarcinoma growth and metastasis.
  • METHODS: Side population (SP) cell analysis and sorting were applied to established human lung adenocarcinoma cell line and an attempt to further enrich them by preliminary serum-free culture before fluorescence activated cell sorting(FACS) was done.
  • RESULTS: Lung cancer cells could grow in a serum-free Medium (SFM) as non-adherent spheres similar to neurospheres or mammospheres.
  • Flow cytometric analysis of cell phenotyping showed that SP cells expressed CD133 and CD44, the common cell surface markers of cancer stem cells, while non-SP cells only expressed CD44.
  • CONCLUSIONS: SP cells existed in human lung adenocarcinoma cell lines and they could be further enriched by preliminary serum-free culture before FACS sorting.
  • SP cells possessed the properties of cancer stem cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • : 11001 Background: Cancer cells possess traits reminiscent of those ascribed to normal stem cells.
  • It is unclear whether these phenotypic similarities between normal/embryonic stem cells and mature tumor cells, specific to lung cancer, are a result of underlying biologic processes, such as specific molecular pathways and regulatory networks.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • GSEA identified gene sets significantly represented in the ES signature: signature of neoplastic transformation, signature of undifferentiated cancer, BRCA pathway, and fibroblast serum response pathway, all associated with cancer invasiveness.
  • The ES signature was not prognostic in prostate, ovarian, or breast adenocarcinomas.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M, Davis W, Silliman C, Trump DL: Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients.
  • We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to flu vaccine in cancer patients.
  • METHODS: Cancer patients at Roswell Park Cancer Institute were offered trivalent (H1N1, H3N2, B/Malaysia) Flu vaccine (Fluzone, 2006-7) and sera collected for hemagglutination inhibition (HI) assay titers.
  • Logistic regression model was used using other covariates such as age, gender, cancer type, and chemotherapy (CT) as controls.
  • RESULTS: 85 patients with colorectal, 35 with prostate, 1 with anal and 1 with gastric adenocarcinoma participated in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961109.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D: Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP).
  • Histological evidence of adenocarcinoma of the prostate was required with clinical stage T<sub>1c</sub> or T<sub>2a</sub> with Gleason 8-10 disease, or clinical stage T<sub>2b</sub>-T<sub>2c</sub> with Gleason grade 7 and PSA of >10 ng/mL, or clinical stage T<sub>3</sub>.
  • Upregulation of apoptosis, proliferation and phosphorylated (p)-Akt have been previously reported in a subset of patients by our group (Ayala GE et al, Clin Cancer Res. 2008;14:7511-8).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Gernone A, Pagliarulo V, Trabucco S: Prognostic role of somatostatin receptor subtypes in human prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16120

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of somatostatin receptor subtypes in human prostate cancer.
  • : e16120 Background: Neuroendocrine differentiation (NED) in prostate carcinoma (PC) is frequently detected by immunohistochemistry as single cells in conventional adenocarcinoma.
  • The absence of SSTR 1 and 5 in more aggressive disease could represent a growth advantage in NED prostate cancer.
  • SSTRs and somatostatin analogs are potential targets for prostate cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963398.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Luu T, Sartor O, Dandade N, Halabi S, Bennett C: Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry. J Clin Oncol; 2009 May 20;27(15_suppl):5131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry.
  • METHODS: The Comprehensive Multicenter Prostate Adenocarcinoma Registry (COMPARE) is an observational registry of men with PSA failure.
  • The median time between cancer diagnosis and registry enrollment was 6 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964431.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Bydder SA, Joseph DJ, Weinstein S, Stuckey BG: Prostate cancer following testosterone replacement in Klinefelter syndrome. ANZ J Surg; 2007 Jan-Feb;77(1-2):93-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer following testosterone replacement in Klinefelter syndrome.
  • However, it may remove the relative protection from adenocarcinoma of prostate, which is otherwise rare in uncomplicated Klinefelter syndrome.
  • We report the case of a 55-year-old man with Klinefelter syndrome who developed prostate cancer after only 7 years of androgen supplementation.
  • We recommend that serum prostate specific antigen (PSA) and digital rectal examinations be carried out during, as well as before androgen replacement.
  • [MeSH-major] Erectile Dysfunction / drug therapy. Hormone Replacement Therapy. Hormones / therapeutic use. Klinefelter Syndrome / complications. Prostatic Neoplasms / chemically induced. Testosterone / therapeutic use


23. Kurokawa T: [A case of giant prostate carcinoma difficult to diagnose because of absence of urinary difficulty]. Hinyokika Kiyo; 2009 Dec;55(12):769-71
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of giant prostate carcinoma difficult to diagnose because of absence of urinary difficulty].
  • The computed tomography revealed a giant pelvic mass with a high value of prostate specific antigen.
  • A transrectal prostatic biopsy was performed and the histopathological diagnosis was poorly differentiated adenocarcinoma of prostate.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048563.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Veshapidze N, Alibegashvili M, Gabunia N, Chigogidze T, Managadze L: Characteristics of morphological change in erythrocytes during metaststic adenocarcinoma of the prostate before and after castration. Georgian Med News; 2009 Jul-Aug;(172-173):10-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of morphological change in erythrocytes during metaststic adenocarcinoma of the prostate before and after castration.
  • For the experimental research we used a blood serum and erythrocytes of 15 men with metastasized adenocarcinoma before castration and a blood serum and erythrocytes of 15 men in 6 months after castration, also a blood serum and erythrocytes of practically healthy men.
  • Deep morphological changes of erythrocytes were observed in peripheral blood during metastasized adenocarcinoma of prostate gland before and after castration.
  • [MeSH-major] Adenocarcinoma / blood. Erythrocytes / pathology. Prostatic Neoplasms / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644180.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


25. Veshapidze N, Chigogidze T, Managadze L, Gabunia N, Kotrikadze N: Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy. Georgian Med News; 2007 Dec;(153):11-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy.
  • The changes of electrophoretic mobility of erythrocytes in the practically healthy men and in men with metastatic prostate cancer before and after castration were studied.
  • Investigation revealed, that the level of electrophoretic mobility of erythrocytes was decreased in the blood of metastatic prostate cancer patients (before castration), as compared with control group and with post operational period data.
  • It was found, that during the malignant adenocarcinoma of prostate (before and after surgery) pathological changes in organism effect erythrocytes superficial membranes and alter their electrical and structural parameters.
  • Probably, that is one of the reasons of considerable decrease of erythrocytes electrophoretic mobility in patients with metastatic prostate adenocarcinoma (before castration).
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Erythrocytes / metabolism. Erythrocytes / ultrastructure. Orchiectomy / methods. Postoperative Care. Preoperative Care. Prostatic Neoplasms / secondary. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250488.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


26. Masue N, Hasegawa Y: [Giant prostate carcinoma treated effectively with endocrine therapy: case report]. Hinyokika Kiyo; 2007 Feb;53(2):133-5
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
  • Computed tomography (CT) and magnetic resonance imaging revealed a giant prostate tumor.
  • The histologic diagnosis was moderately differentiated adenocarcinoma of prostate.
  • Four months later, CT showed that the tumor had decreased markedly in size, and the serum prostate specific antigen level was within normal range.
  • Hormone refractory prostate cancer was not found 1 year after the start of treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chlormadinone Acetate / therapeutic use. Goserelin / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Aged, 80 and over. Anilides / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Humans. Magnetic Resonance Imaging. Male. Naphthalenes / administration & dosage. Nitriles. Piperazines / administration & dosage. Prostate-Specific Antigen / blood. Tosyl Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Naphthalenes; 0 / Nitriles; 0 / Piperazines; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; 0SY050L61N / Chlormadinone Acetate; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen; R9PHW59SFN / naftopidil
  •  go-up   go-down


27. Tochigi T, Yasufuku K, Nakajima T, Fujiwara T, Kubota K, Takahashi Y, Yoshino I: Initial Diagnosis of Mediastinal Lymph Node Metastases From Prostate Cancer by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration. J Bronchology Interv Pulmonol; 2009 Jan;16(1):59-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial Diagnosis of Mediastinal Lymph Node Metastases From Prostate Cancer by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration.
  • Endobronchial ultrasound-guided transbronchial needle aspiration was performed; cytology revealed adenocarcinoma, whereas histology contained adenocarcinoma of prostate origin.
  • Immunohistochemistry was strongly positive for prostate-specific antigen and prostate-specific acid phosphate for confirmation of metastases from the prostate cancer and negative for thyroid transcription factor-1.
  • Hence, the patient was diagnosed as having lymph node metastasis from a prostate cancer.
  • After the initial diagnosis, needle biopsy of the prostate was performed, and prostate cancer was confirmed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23168473.001).
  • [ISSN] 1944-6586
  • [Journal-full-title] Journal of bronchology & interventional pulmonology
  • [ISO-abbreviation] J Bronchology Interv Pulmonol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Sekine Y, Ito K, Yamamoto T, Nakazato H, Shibata Y, Hatori M, Suzuki K: Pretreatment total testosterone levels in patients with prostate cancer in the past two decades in Japan. Cancer Detect Prev; 2007;31(2):149-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment total testosterone levels in patients with prostate cancer in the past two decades in Japan.
  • We studied the association of pretreatment total testosterone levels with the clinical stage and histological grade of prostate cancer.
  • Patients with poorly differentiated adenocarcinoma had significantly lower testosterone levels than those with the others (versus well; p<0.01, moderately; p<0.01).
  • CONCLUSIONS: Newly diagnosed patients with poorly differentiated adenocarcinoma of prostate have lower testosterone levels than the others.
  • [MeSH-major] Adenocarcinoma / blood. Prostatic Neoplasms / blood. Testosterone / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418977.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


29. Prosvic P, Brod'ák M, Odrázka K, Morávek P: [A case of an asynchronic triple tumorous disorder: a rectal adenocarcinoma, a carcinoma of the kidney and a prostatic adenocarcinoma--case report]. Rozhl Chir; 2005 Jan;84(1):41-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of an asynchronic triple tumorous disorder: a rectal adenocarcinoma, a carcinoma of the kidney and a prostatic adenocarcinoma--case report].
  • [Transliterated title] Asynchronní triplicitní výskyt nádorového onemocnĕní: adenokarcinomu rekta, karcinomu ledviny a adenokarcinomu prostaty--kazuistika.
  • In the year 1980 in 56 years old patient had histologically proven rectal adenocarcinoma and consequently was done radical Miles amputation of rectum.
  • In December 1991 in the same patient was histologically proven well differentiated adenocarcinoma of prostate after transurethral resection of prostate.
  • Prostate cancer was threated bilateral orchiectomy (March 1992) and consequently from April to June 1992 was done small-volume irradiation of pelvic by Betatron X-ray, box technique with dosage 70 Gy.
  • Patient was died of generalisation renal cancer in the February 1998.
  • The carcinoma of prostate and rectum wasn't found in the autopsy.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Renal Cell. Kidney Neoplasms. Neoplasms, Second Primary. Prostatic Neoplasms. Rectal Neoplasms

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813456.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


30. Kapoor N, Jain R, Surange S, Bhardwaj VK, Srivastava A: Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate. Indian J Pathol Microbiol; 2006 Apr;49(2):178-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
  • The search for a perfect tumour marker, which would be able to distinguish benign from malignant enlargement of prostate accurately, is still not complete.
  • Total Prostate Specific Antigen (TPSA), a good test, has it's own inadequacies but Free Prostate Specific Antigen (FPSA) to TPSA ratio is emerging as a better adjuvant to it.
  • This prospective study was done to verify the utility of FPSA to TPSA ratio in diagnosis of malignancy of prostate and its relationship to Gleason grading (indicating the aggressiveness) of adenocarcinoma of prostate.
  • 100 patients with urinary symptoms, who were above fifty years of age and had prostatic enlargement, formed the study group.
  • Prostatic biopsy of all the cases was obtained and diagnostic histopathology and Gleason grading (in cases where adenocarcinoma was diagnosed) was done.
  • Thus making it very obvious that FPSA to TPSA ratio is an excellent adjuvant to TPSA for diagnosis of malignancy of prostate increasing the specificity and predictive value for positive test.
  • An inverse correlation (correlation coefficient = -0.95) was also found between PSA ratio and aggressiveness of prostate cancer, pointing towards its capability to predict the histological (Gleason) grade of the tumour.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933710.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


31. Takahashi S, Takeshita K, Seeni A, Sugiura S, Tang M, Sato SY, Kuriyama H, Nakadate M, Abe K, Maeno Y, Nagao M, Shirai T: Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate; 2009 May 1;69(6):644-51
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling.
  • BACKGROUND: Epidemiological data indicate that intake of one form of vitamin E, gamma-tocopherol, may reduce prostate cancer risk, and several in vitro studies have demonstrated that gamma-tocopherol can inhibit prostate cancer cell growth.
  • The purpose of the present study was to confirm effects of gamma-tocopherol on prostate cancer in the transgenic rat for adenocarcinoma of prostate (TRAP) model established in our laboratory.
  • However, quantitative evaluation of prostatic lesions demonstrated significantly suppression of sequential progression from PIN to adenocarcinoma in a dose-dependent manner, along with clear activation of caspases 3 and 7 in the ventral lobe in both experiments.
  • CONCLUSIONS: The present study clearly demonstrated that gamma-tocopherol suppresses prostate tumor progression in an in vivo TRAP model, and could be a candidate chemopreventive agent for human prostate cancer.
  • [MeSH-major] Adenocarcinoma / prevention & control. Prostatic Neoplasms / prevention & control. gamma-Tocopherol / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19143023.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Ceramides; 0 / Isoenzymes; 1406-66-2 / Tocopherols; 8EF1Z1238F / gamma-Tocopherol; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


32. Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL: In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res; 2005 May 15;11(10):3930-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AVI-4126, a PMO targeted against c-MYC, has been extensively characterized in multiple cancer and other disease models and is currently in human clinical trials.
  • A phase I clinical study was conducted to address the issue of PMO bioavailability in malignant tumors surgically excised from patients with adenocarcinoma of prostate and breast 1 day after i.v. administration of a single dose of 90 mg AVI-4126 PMO.
  • Significant concentrations of intact PMO similar to the animal models were detected in both human prostate and breast tumor tissues with increased distribution in the tumor core for the vascular breast tumors.
  • No serious adverse events (graded according to National Cancer Institute Common Toxicity Criteria) were reported.
  • These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials.
  • [MeSH-major] Breast Neoplasms / drug therapy. Morpholines / adverse effects. Morpholines / pharmacokinetics. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897595.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Morpholines; 0 / Morpholinos
  •  go-up   go-down


33. Leewansangtong S, Vorrakitkatorn P, Amornvesukit T, Taweemonkongsap T, Nualyong C, Sujijantararat P: Laparo-endoscopic single site (LESS) robotic radical prostatectomy in an Asian man with prostate cancer: an initial case report. J Med Assoc Thai; 2010 Mar;93(3):383-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparo-endoscopic single site (LESS) robotic radical prostatectomy in an Asian man with prostate cancer: an initial case report.
  • MATERIAL AND METHOD: A 71 year-old man with adenocarcinoma of prostate presented at Faculty of Medicine Siriraj Hospital, Bangkok.
  • Prostate-specific antigen level was 16.5 ng/ml and digital rectal examination approximately showed 30 gram prostate with nodule in both lobes.
  • [MeSH-major] Laparoscopy / methods. Prostatectomy / methods. Prostatic Neoplasms / surgery. Robotics

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420116.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


34. Genadiev Ts, Gaĭdarov D, Veleva V, Khandzhiev I, Petrov P: [Laparoscopic pelvic lymph node dissection-- method for prostate cancer staging]. Khirurgiia (Sofiia); 2007;(6):13-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic pelvic lymph node dissection-- method for prostate cancer staging].
  • INTRODUCTION: Laparoscopic pelvic lymph node dissection is recently widely used method for surgical staging for prostate cancer.
  • MATERIALS AND METHODS: Between April 2003 and December 2006 in our Clinic have been operated 20 patients with adenocarcinoma of prostate.
  • Median prostate specific antigen was 53.7 ng/ml.
  • Clinical methods - digital rectal examination of prostate, transrectal ultrasound punction biopsy of prostate, level of hemoglobin in blood to evaluate the blood loss.
  • This method is a useful for minimally invasive staging of prostate cancer.
  • [MeSH-major] Laparoscopy / methods. Lymph Node Excision. Lymph Nodes. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622375.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


35. Curtis MW, Evans AJ, Srigley JR: Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity. Mod Pathol; 2005 Apr;18(4):585-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity.
  • The differential diagnosis of mucin-producing adenocarcinoma of the prostate includes conventional prostatic adenocarcinoma with mucin production, secondary adenocarcinoma usually of colorectal origin and, very rarely, urothelial-type adenocarcinoma arising from either the prostatic urethra or proximal ducts.
  • Conventional prostatic adenocarcinoma with mucin production is readily identified by routine microscopy and immunohistochemistry.
  • The distinction between secondary adenocarcinoma and urothelial-type adenocarcinoma, however, can present a significant diagnostic challenge.
  • In addition, documented examples of the latter in the prostate are exceptionally rare.
  • A transurethral resection of prostate specimen and prostatic needle biopsies from two patients showing urothelial-type adenocarcinoma of the prostate were identified in our consultation files.
  • Transurethral resection of prostate material from two patients with clinically confirmed secondary adenocarcinoma of colonic origin involving the prostate and a prostatectomy specimen with mucinous conventional prostatic adenocarcinoma were also identified for comparison purposes.
  • Formalin-fixed, paraffin-embedded sections were stained for prostate-specific antigen (PSA), prostatic acid phosphatase, carcinoembryonic antigen, cytokeratin 7, cytokeratin 20 and high molecular weight cytokeratin 34betaE12.
  • The urothelial-type adenocarcinoma cases were diffusely positive for cytokeratin 7 and focally positive for 34betaE12 and cytokeratin 20, consistent with an origin from the urothelium of the prostatic urethra or proximal prostatic ducts.
  • In contrast, the secondary adenocarcinoma of colonic origin cases were diffusely cytokeratin 20 positive and either negative or focally positive for cytokeratin 7 and negative for 34betaE12.
  • The mucinous conventional prostatic adenocarcinoma was positive for PSA and prostatic acid phosphatase and negative for cytokeratin 7, cytokeratin 20 and 34betaE12.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Aged, 80 and over. Carcinoembryonic Antigen / analysis. Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Keratin-20. Keratin-7. Keratins / analysis. Male. Middle Aged. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778694.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Carcinoembryonic Antigen; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


36. Kitamoto K, Hayashi T, Tamada S, Ezaki K, Kawashima H, Sugimura K, Nakatani T: [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report]. Hinyokika Kiyo; 2005 Jan;51(1):33-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
  • Prostatic neuroendocrine (NE) carcinoma is a rare disease with a poor prognosis because of its rapid progression and the androgen-independent characteristic, for which no successful therapy is available presently.
  • We report a case of NE differentiated prostate cancer, which was diagnosed as adenocarcinoma initially and progressed with NE differentiation during the combined androgen blockade therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Androgen Antagonists / therapeutic use. Carcinoma, Neuroendocrine / pathology. Cell Transformation, Neoplastic / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732339.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


37. Hussein K, Nanda A, Al-Sabah H, Alsaleh QA: Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder. J Eur Acad Dermatol Venereol; 2005 Sep;19(5):597-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder.
  • In the present report, we describe an 82-year-old male with SS in association with adenocarcinoma of the prostate and transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / diagnosis. Prostatic Neoplasms / pathology. Sweet Syndrome / diagnosis. Urinary Bladder Neoplasms / pathology


38. Neulander EZ, Wajsman Z, Greene GF: Radical prostatectomy and postoperative radiation in patients with adenocarcinoma of prostate of intermediate and high risk for recurrence. J Ark Med Soc; 2005 Mar;101(9):276-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical prostatectomy and postoperative radiation in patients with adenocarcinoma of prostate of intermediate and high risk for recurrence.
  • METHODS: Eighty-five consecutive patients categorized as intermediate (17.5%) and high risk (82.5%) of failure after definitive therapy for carcinoma of prostate according to the National Comprehensive Cancer Network (NCCN) underwent RP between 1989 and 1997.
  • Cancer-specific mortality was 3.5%.
  • CONCLUSIONS: In the intermediate and high-risk groups of patients with nonpalpable prostate cancer, RP and adjuvant RT may provide a biochemical recurrence-free rate (bRFR) comparable to that reported in other series with RP alone on patients in the low-risk groups.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787077.001).
  • [ISSN] 0004-1858
  • [Journal-full-title] The Journal of the Arkansas Medical Society
  • [ISO-abbreviation] J Ark Med Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Quan AL, Ciezki JP, Reddy CA, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, De Oreo G, Klein EA: Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate. Urology; 2006 Dec;68(6):1237-41
MedlinePlus Health Information. consumer health - Prostate Cancer Screening.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate.
  • OBJECTIVES: To analyze whether prostate size affects biochemical relapse-free survival (bRFS).
  • All patients were treated with iodine-125 alone as the radiotherapeutic modality and had a minimum of four posttreatment prostate-specific antigen values.
  • The factors examined in the univariate and multivariate analyses predicting for bRFS included gland volume, patient age, initial prostate-specific antigen value, biopsy Gleason score, clinical stage, and postimplant dosimetric variables.
  • On separate multivariate analyses, only the pretreatment prostate width and volume significantly influenced bRFS favorably (P = 0.0069 and P = 0.0255, respectively).
  • No association was found between gland size/width and postimplant dosimetry.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Brachytherapy / instrumentation. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169646.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


40. Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K: [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases]. Hinyokika Kiyo; 2007 Jul;53(7):489-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
  • We report two cases of combined small-cell carcinoma (SCC) and adenocarcinoma of prostate.
  • Whole body computed tomography (CT) revealed prostatic swelling, pancreatic mass, para-aortic lymphadenopathies, and multiple lung nodules.
  • Elevation of tumor markers (prostate specific antigen [PSA, 1,760 ng/ml] and neuron-specific enolase [NSE, 88 ng/ml]) was noted.
  • Needle biopsy of the prostate demonstrated both SCC and adenocarcinoma.
  • The patient died three months after the diagnosis.
  • The symptom and elevated serum PSA (23.1 ng/ml) prompted prostatic needle biopsy, which demonstrated combined SCC/adenocarcinoma.
  • Treatment of combined SCC and adenocarcinoma of prostate poses a dilemma.
  • In Case 1, MAB was effective for adenocarcinoma but not for SCC.
  • Much remains to be elucidated to better manage combined SCC/adenocarcinoma of prostate.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Small Cell. Neoplasms, Multiple Primary. Prostatic Neoplasms
  • [MeSH-minor] Aged. Androgen Antagonists / therapeutic use. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Male. Phosphopyruvate Hydratase / blood. Prostate-Specific Antigen / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702184.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


41. Barbón JJ, González-Tuero J, Gay LL, Pérez-García FJ, Sampedro A: [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy]. Arch Soc Esp Oftalmol; 2007 Nov;82(11):715-7
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
  • [Transliterated title] Regresión de una metástasis coroidea de adenocarcinoma de próstata con tratamiento hormonal.
  • CASE REPORT: We report a case of a patient diagnosed with prostatic adenocarcinoma with multiple bone metastases and a choroidal metastasis in his left eye.
  • DISCUSSION: Complete resolution of choroidal metastases of prostatic adenocarcinoma with hormonal therapy is exceptional, but the effect of this treatment on such metastases should be observed before recommending radiation therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Choroid Neoplasms / secondary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged. Biopsy. Bone Neoplasms / secondary. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Prostate / pathology. Prostate-Specific Antigen / blood. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979041.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


42. Chuang AY, Epstein JI: Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1225-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma.
  • Prostatic xanthoma may mimic high-grade prostatic adenocarcinoma or prostate cancer treated with hormone therapy.
  • From 1995 to 2006, 40 cases of prostatic xanthoma were diagnosed at The Johns Hopkins Hospital.
  • Xanthoma was found on needle biopsy in 25 cases, with 2 cases noted on transurethral resection of prostate.
  • Twenty-six cases contained only 1 focus of prostatic xanthoma with 1 case having 3 foci on the same core biopsy specimen.
  • Ten xanthomas consisted of cords and individual cells infiltrating the prostatic stroma, further mimicking high-grade prostate carcinoma.
  • One of 15 (6.7%), 2/17 (11.8%), and 1/12 (8.3%) cases were positive for prostate-specific antigen, prostate-specific acid phosphatase, and alpha-methylacyl-CoA racemase, respectively.
  • Careful attention to morphology with adjunctive use of CD68 and CAM5.2 immunohistochemical stains are helpful in the diagnosis of prostatic xanthoma, especially in difficult cases with an infiltrative pattern.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Biomarkers / metabolism. Biopsy, Needle. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Male

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667547.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


43. Primavera V, Querques G, Guigui B, Turco I, Iaculli C, Russo V, Delle Noci N: [Choroidal metastasis from clinically regressed prostate adenocarcinoma: imaging of a rare case]. J Fr Ophtalmol; 2008 Nov;31(9):877-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis from clinically regressed prostate adenocarcinoma: imaging of a rare case].
  • [Transliterated title] Métastase choroïdienne d'un adénocarcinome de la prostate: iconographie d'un cas rare.
  • We report a rare case of prostatic adenocarcinoma metastases at the choroids, diagnosed and followed by fluorescein angiography (FA), indocyanine-green angiography (ICGA), and optical coherence tomography (OCT-3 Stratus).
  • The systemic workup, including hematologic analysis and total-body computed tomography (CT), revealed elevated serum prostate-specific antigen (PSA) and alkaline phosphatase, extensive abnormalities of the axial skeleton, and nodular pulmonary shadows; therefore, prostatic adenocarcinoma was suspected.
  • Needle biopsies (prostatic and pulmonary) confirmed adenocarcinoma of the prostate, with metastatic disease.
  • DISCUSSION: Prostatic carcinoma should be considered in any male patient with a choroidal mass suspected of being a metastasis.
  • In our patient, FA, ICGA, and OCT clearly documented the complete regression of choroidal metastasis from prostatic carcinoma.
  • Fluorescein angiography, indocyanine-green angiography, and optical coherence tomography are useful tools in the diagnosis and follow-up of prostatic adenocarcinoma metastatic to the choroid.
  • [MeSH-major] Adenocarcinoma / secondary. Choroid Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107059.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


44. San Miguel Fraile P, Dos Santos JE, Pélaez Boismorand E, Ortiz Rey JA, Iglesias Rodríguez B, Cambronero Santos J, Fajardo Seijo JL, Rodríguez Costas JM, Fernández Regueiro M: [Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma]. Actas Urol Esp; 2005 Jan;29(1):64-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma].
  • [Transliterated title] Estudio de la expresión de cerbB-2 en el adenocarcinoma de próstata.
  • OBJECTIVES: Our aim is to determine the expression of the cerbB-2 oncoprotein in prostate cancers using an immunohistochemistry staining and to compare these results with several clinical and histological prognostic factors.
  • METHODS: An immunohistochemical staining using the cerbB-2 monoclonal antibody (Dako) was performed in 32 radical prostatectomy specimens diagnosed of adenocarcinoma.
  • 1) This study shows that 44% of all prostate cancer express the cerbB-2 oncoprotein with immunohistochemical technique.
  • 2) These findings suggest that is necessary to standardize the immunohistochemical staining procedure with cerbB-2 in prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786765.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


45. Barbosa PF, Malafaia O, Ribas-Filho JM, Czeczko NG, Ribas CM, Cuenca RM, Chula DC: [Cytophotometric expression of tumor antigen markers Ki-67 and CD-34 in prostate adenocarcinoma]. Rev Col Bras Cir; 2009 Dec;36(6):498-503
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytophotometric expression of tumor antigen markers Ki-67 and CD-34 in prostate adenocarcinoma].
  • [Transliterated title] Estudo citofotométrico da expressão dos marcadores tumorais Ki-67 e CD34 no adenocarcinoma de próstata.
  • OBJECTIVE: To quantify the percentage of immunostaining through the labeling index as well as the optical density of Ki-67 and CD34 in prostate adenocarcinoma and compare the results between markers.
  • METHODS: Markers Ki-67 and CD34 were studied using immunohistochemistry in 34 cases of prostate adenocarcinoma from radical prostatectomies performed at the Hospital Regional do Gama in Brasilia, Brazil from 2000 through 2005.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Ki-67 Antigen / metabolism. Prostatic Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140393.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


46. Cotrina Monroy AP, López López A, Ruiz Solis S, Gómez Embuena A: [Incidental finding of a meningioma-en-plaque in a patient with prostate adenocarcinoma]. Rev Esp Med Nucl; 2010 Sep-Oct;29(5):254-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental finding of a meningioma-en-plaque in a patient with prostate adenocarcinoma].
  • [Transliterated title] Hallazgo incidental de un meningioma en placa en un paciente con adenocarcinoma de próstata.
  • We present a case of a large MEP, which was an incidental finding on a scintigraphy study of a patient with prostate adenocarcinoma, this finding being histologically confirmed.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Incidental Findings. Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Neoplasms, Multiple Primary / radionuclide imaging. Prostatic Neoplasms / radionuclide imaging
  • [MeSH-minor] Aged. Craniocerebral Trauma / radionuclide imaging. Diagnosis, Differential. Diagnostic Errors. Exophthalmos / etiology. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Osteitis Deformans / radionuclide imaging. Radiopharmaceuticals. Skull Neoplasms / radionuclide imaging. Skull Neoplasms / secondary. Technetium Tc 99m Medronate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 20398966.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


47. Morán Pascual E, Dicapua Sacoto C, Trassierra Villa M, Pontones Moreno JL, Ruiz Cerdá JL, Jiménez Cruz JF: [Watchful waiting in incidental adenocarcinoma of the prostate]. Actas Urol Esp; 2010 Nov;34(10):854-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Watchful waiting in incidental adenocarcinoma of the prostate].
  • [Transliterated title] Actitud expectante en el adenocarcinoma incidental de próstata.
  • OBJECTIVE: To describe the outcome of patients diagnosed of incidental prostate adenocarcinoma managed by watchful waiting.
  • MATERIAL AND METHODS: We included patients with PSA< 4 ng/mL or higher with previous negative biopsy, who underwent surgery for BPH being diagnosed of incidental prostate adenocarcinoma.
  • We performed a descriptive and retrospective study in patients with this diagnosis between 1992 and 2007.
  • Progression variables were: age, preoperative and postoperative PSA, stage, Gleason score, prostate volume, initial treatment, PSA evolution and salvage treatment if necessary.
  • RESULTS: 47 patients were diagnosed of incidental prostatic adenocarcinoma, finding an incidence of 4.25%.
  • CONCLUSION: Watchful waiting is a useful option in patients with incidental prostate adenocarcinoma and favourable prognostic criteria.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Watchful Waiting

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159280.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


48. Bantis A, Gonidi M, Athanassiades P, Tsolos Ch, Liossi A, Aggelonidou E, Athanassiadou AM, Petrakakou E, Athanassiadou P: Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors. J Exp Clin Cancer Res; 2005 Jun;24(2):273-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors.
  • The ability to accurately predict tumor behavior and patient survival is a problem in managing patients with prostate cancer.
  • DNA ploidy provides important information for the evaluation of the prognosis of prostate cancer.
  • The aim of this study was to investigate the DNA ploidy in imprints from prostate adenocarcinomas in a group of 70 patients in relation to Gleason score, tumor differentiation, stage and PSA serum levels.
  • Our results conclude that DNA ploidy status appears to be an additional marker in the field of prognosis of prostatic adenocarcinoma and could provide useful information on the potential behavior of prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. DNA / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110761.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


49. Abaza R, Diaz LK Jr, Laskin WB, Pins MR: Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy. J Urol; 2006 Dec;176(6 Pt 1):2701-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
  • PURPOSE: Discovery of prostatic adenocarcinoma limited to transurethral resection material generates a treatment dilemma.
  • We investigated the usefulness of parameters shown to be associated with prognosis in prostate cancer (p53 and bcl-2 immuno-expression, DNA cell cycle analysis and Gleason score) to stratify these incidentally identified tumors to guide clinical decision making.
  • MATERIALS AND METHODS: Paraffin embedded tissues from transurethral prostate resection specimens containing T1a prostate adenocarcinoma from 44 patients who underwent resection between 1980 and 1990 were immunostained for p53 and bcl-2, and subjected to flow cytometry to determine DNA ploidy.
  • Statistical relationships among these 4 variables, tumor progression and cancer specific survival were analyzed.
  • RESULTS: Six of 44 patients in the study population had cancer progression.
  • Only 2 tumors studied were aneuploid and neither of these 2 patients had cancer progression.
  • Only Gleason score was a significant predictor of cancer progression on univariate and multivariate Cox regression analysis (p = 0.045 and 0.046, respectively).
  • CONCLUSIONS: For T1a prostate cancer incidentally detected on transurethral prostate resection p53 and bcl-2 immuno-expression, and DNA ploidy do not predict survival or disease progression.
  • [MeSH-major] Adenocarcinoma / genetics. Incidental Findings. Prostatectomy. Prostatic Neoplasms / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Flow Cytometry. Humans. Immunohistochemistry. Male. Middle Aged. Ploidies. Prognosis. Prostatic Diseases / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085199.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


50. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH: BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer; 2006 Oct 15;119(8):1858-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF and KRAS mutations in prostatic adenocarcinoma.
  • RAS mutations are known to occur in prostate adenocarcinomas, but little is known about BRAF mutations in these tumors.
  • In the present study, BRAF and KRAS mutations were characterized in 206 prostate adenocarcinomas by enhanced PCR-RFLP and direct sequencing.
  • Mutations in codon 600 of BRAF were identified in 21 (10.2%) of 206 prostate adenocarcinomas.
  • KRAS mutations in codons 12 or 13 were found in 15 (7.3%) of 206 prostate adenocarcinomas.
  • Prostate adenocarcinomas with a BRAF mutation tended to show higher preoperative serum PSA levels, Gleason scores and tumor stages than prostate adenocarcinomas with a KRAS mutation.
  • The results obtained show that BRAF mutations are as uncommon as KRAS mutations in prostate adenocarcinoma.
  • Although BRAF and KRAS are members of the same RAS/ERK signaling pathway, prostate adenocarcinomas with a BRAF mutation showed clinicopathologic features that differed from those of prostate adenocarcinoma with a KRAS mutation.
  • [MeSH-major] Adenocarcinoma / genetics. Oncogene Protein p21(ras) / genetics. Prostatic Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics


51. Wan Muhaizan WM, Ahmad PK, Phang KS, Arni T: p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma. Malays J Pathol; 2006 Dec;28(2):93-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma.
  • OBJECTIVES: This study was carried out to determine the role of p53 and p21 in the pathogenesis of prostatic adenocarcinoma and their association with tumour grade.
  • METHOD: Sixty-seven histologically confirmed prostatic adenocarcinoma cases collected from Hospital Universiti Kebangsaan Malaysia and General Hospital Kuala Lumpur were studied.
  • RESULTS: IHC positivity for p53 was expressed in 1/2 (50%) low grade, 14/33 (42%) intermediate grade, and 21/32 (66%) high grade tumours. p21 was expressed in 0/2 low grade, 16/33 (48%) intermediate grade and 15/32 (47%) high grade tumours. p53 and p21 expressions did not show statistically significant correlation with the different grades of prostatic adenocarcinoma or with each other (p = 0.42).
  • CONCLUSION: Although the p53 positivity rate was higher in high-grade prostate adenocarcinoma, this was not statistically significant.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Prostatic Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376798.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


52. Mohamed MA, Greif PA, Diamond J, Sharaf O, Maxwell P, Montironi R, Young RA, Hamilton PW: Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int; 2007 Apr;99(4):908-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
  • OBJECTIVE: To explore the nuclear chromatin phenotype, overall epigenetic mechanisms, chromatin remodelling enzymes and their role as diagnostic biomarkers in prostate lesions, using high-resolution computerized quantitative digital image analysis (DIA).
  • MATERIALS AND METHODS: A tissue microarray (TMA) was constructed using paraffin wax-embedded prostatic tissues from 78 patients, containing 30 cores of benign prostatic hyperplasia (BPH), 10 of low-grade prostatic intraepithelial neoplasia (LGPIN), 38 of prostate adenocarcinoma, 20 of BPH tissue excised at 0.6-1 mm from LGPIN lesions, and 10 of BPH prostatic tissues obtained 0.6-1 mm from high-grade PIN (HGPIN) lesions.
  • In PIN lesions, there was a high chromatin content with DNA-hypermethylation, while in prostatic adenocarcinoma there was a lower chromatin content with DNA-hypomethylation and H3K9-hypoacetylation.
  • CONCLUSIONS: The present study confirms the ability of high-resolution computerized digital imaging of nuclear texture features to detect changes in chromatin phenotype, epigenetic events and the presence of chromatin remodelling, factors that can be used to distinguish between different prostatic pathologies, i.e.
  • BPH, LGPIN, HGPIN and prostate adenocarcinoma, and further allow the detection of MAC near PIN lesions.
  • Further studies are needed to elucidate the complex interplay between chromatin structure, its modifications and the progression of prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromatin. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378849.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin
  •  go-up   go-down


53. Aydin H, Zhou M, Herawi M, Epstein JI: Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy. Hum Pathol; 2005 Nov;36(11):1172-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy.
  • There is limited published data regarding the significance of the number or position of nucleoli and the presence of apoptotic bodies in diagnostically challenging cases of adenocarcinoma of the prostate on needle biopsy material.
  • One hundred consecutive prostate cancers on needle biopsy were sent because of diagnostic difficulty to an expert in urological pathology, and the remaining normal benign prostatic glands on the same core were evaluated for the number and location of nucleoli and for the presence of mitotic figures and apoptotic bodies.
  • For comparison, the same parameters were evaluated in mimickers of cancer on needle biopsy from other cases, including partial atrophy (n = 135), fully developed atrophy (n = 89), adenosis (n = 50), prostate glands with acute inflammation (n = 50), and high-grade prostatic intraepithelial neoplasia (n = 100).
  • Although the number and position of nucleoli did not discriminate between cancer and benign mimickers, mitotic figures and apoptotic bodies were more commonly seen in cancer.
  • Apoptotic bodies in particular were seen fairly frequently (34%) in prostatic adenocarcinoma (also seen in 13% of high-grade prostatic intraepithelial neoplasia), yet rarely in benign mimickers on needle biopsy.
  • Our findings indicate that the presence of apoptotic bodies should be added to the list of histological features that are helpful in the diagnosis of challenging cases of prostate cancer on needle biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Cell Nucleolus / pathology. Inclusion Bodies / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Apoptosis / physiology. Biopsy, Needle. Humans. Immunohistochemistry. Male. Prostatic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260270.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


54. Torlakovic E, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fosså SD: Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int J Cancer; 2005 Nov 10;117(3):381-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma.
  • The expression, distribution and the role of steroid receptors in benign and malignant untreated prostate tissues is well recognized, however, the status of steroid receptors in prostate after radiotherapy (RT) for adenocarcinoma has not yet been studied fully.
  • Immunohistochemical evaluation of androgen receptor (AR), estrogen receptor-alpha (ER-alpha), estrogen receptor-beta (ER-beta), and progesterone receptor (PR) was carried out in prostate needle biopsies obtained before and after radiotherapy from 60 patients with adenocarcinoma.
  • The ER-beta transcripts were also studied by RT-PCR in LNCaP prostate carcinoma cell line before and 24 hr after gamma-irradiation at 0.5 Gy and 8.0 Gy.
  • Significantly higher level of ER-beta expression was found in post-radiation samples of prostate adenocarcinoma and benign epithelium.
  • After RT, all steroid receptors were upregulated in prostatic stroma.
  • Although a positive association between AR and ER-beta expression was observed in pre-treatment prostate adenocarcinoma, it was lost after RT suggesting that these 2 steroid receptors respond differently to RT.
  • Upregulation of all steroid receptors in the prostate stroma and upregulation of ER-beta in the tumor epithelium after RT, may represent a protective tissue response to radiation-induced tissue injury.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / radiotherapy. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / genetics. Prostatic Neoplasms / radiotherapy. Receptors, Steroid / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900599.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Steroid
  •  go-up   go-down


55. Samaratunga H, Samaratunga D, Perry-Keene J, Adamson M, Yaxley J, Delahunt B: Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration. Pathology; 2010 Jun;42(4):330-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration.
  • AIMS: Seminal vesicle (SV) invasion by prostatic adenocarcinoma is a poor prognostic indicator.
  • This study examines the distribution of invasive prostatic adenocarcinoma in SVs and makes recommendations regarding sampling procedures.
  • The site of invasive prostatic carcinoma within the muscular wall of the SV and its presence in the ejaculatory duct was recorded.
  • Patients ranged in age from 52 to 73 years (mean 64 years), with a serum prostatic specific antigen ranging from 3.7 to 46 ng/mL (mean 10.6 ng/mL).
  • All but one of the SV positive cases (98.2%) had involvement of the proximal third (15 right, 17 left and 23 both) of the gland, 35 of which (63.6%) had infiltration only of the proximal SV.
  • Lymphovascular invasion within the prostate was seen in 71.4% of cases.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Seminal Vesicles / pathology
  • [MeSH-minor] Aged. Digital Rectal Examination. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438404.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


56. Castro Gómez JE, Anido Herranz U, Carballo Castro A, Gómez Caamaóo A, León Mateos LA, Porto Vázquez C, López López R: Brain metastases from prostate adenocarcinoma. Clin Transl Oncol; 2009 Jan;11(1):63-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from prostate adenocarcinoma.
  • Brain metastases of prostate adenocarcinoma are rare.
  • We report a case of brain metastases from prostate adenocarcinoma 15 months after the diagnosis of the primary tumour.
  • The biopsy performed showed metastatic prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155207.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. Hussein MR, Al-Assiri M, Musalam AO: Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol; 2009 Apr;86(2):108-13
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
  • BACKGROUND: Immune cell infiltrate is a constant feature in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
  • This study elaborates on the cells of the immune system present in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
  • HYPOTHESIS: Here, we hypothesized that "the development of benign nodular prostatic hyperplasia and prostatic adenocarcinoma is associated with numeric alterations of the immune cell infiltrate".
  • MATERIALS AND METHODS: A total of 50 transurethral prostatic resection specimens, each entailing normal prostate, benign nodular prostatic hyperplasia and high grade prostatic adenocarcinoma were evaluated for the density and phenotype of the immune cells using immunohistological methods and mouse monoclonal antibodies decorating T cells (CD3), histiocytes (CD68) and B lymphocytes (CD20).
  • We observed variations in the density of the immune cells among the normal prostate, benign nodular prostatic hyperplasia and high grade prostatic adenocarcinoma.
  • Compared with normal prostate, benign nodular prostatic hyperplasia had a statistically significant high density of immune cells (3.4+/-0.4versus 13.5+/-1.0, P<0.00).
  • In contrast, a significant decrease in the counts of these cells was observed in high-grade prostatic adenocarcinoma compared to benign nodular prostatic hyperplasia (13.5+/-1.0 versus 5.2+/-0.3, P<0.01).
  • CONCLUSIONS: The increased density of immune cells (predominantly CD(+)3 T cells) in benign nodular prostatic hyperplasia suggests that the initial response to cellular damage is mediated by cell-mediated immunity.
  • The decreased density of immune cells in high-grade prostatic adenocarcinoma may reflect immunosuppression.
  • [MeSH-major] Cell Movement. Immune System / cytology. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology


58. Baydar DE, Ozen H, Geyik PO, Gurel B: Can telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary study. Pathol Res Pract; 2010 Oct 15;206(10):700-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary study.
  • Telomere shortening can be one of the ways that cause chromosomal instability in the pathogenesis of prostatic carcinoma.
  • In the current study, we evaluated telomere length (TL) in normal and malignant prostate tissues, and its association with prognostic factors and with time to biochemical tumor recurrence.
  • The majority (49/61) of prostate cancers displayed abnormally short telomeres.
  • Telomere shortening is a common alteration in prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Prostatic Neoplasms / genetics. Telomere / metabolism
  • [MeSH-minor] Aged. Disease-Free Survival. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pilot Projects. Proportional Hazards Models. Prostate-Specific Antigen / blood. Prostatectomy. Risk Assessment. Risk Factors. Time Factors. Tissue Array Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20674190.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


59. Prieto MC, Matousek P, Towrie M, Parker AW, Wright M, Ritchie AW, Stone N: Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue. J Biomed Opt; 2005 Jul-Aug;10(4):44006
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue.
  • Prostate samples for this study were obtained by taking a chip at the transurethral resection of the prostate (TURP), and bladder samples from a biopsy taken at transurethral resection of bladder tumor (TURBT) and TURP.
  • Spectra obtained through the bladder and prostate gland tissue, at different time delays after the laser pulse, clearly show change in the spectra as depth profiling occurs, eventually showing signals from the uric acid cell and urea cell, respectively.
  • We show for the first time, using this novel technique, that we are able to obtain spectra from different depths through both the prostate gland and the bladder.
  • This has major implications in the future of Raman spectroscopy as a tool for diagnosis.
  • With the help of Raman spectroscopy and Kerr gating, it may be possible to pick up the spectral differences from a small focus of adenocarcinoma of the prostate gland in an otherwise benign gland, and also stage the bladder cancers by assessing the base of the tumor post resection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / diagnosis. Spectrum Analysis, Raman / methods. Urinary Bladder Neoplasms / chemistry. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Algorithms. Artifacts. Humans. Male. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178640.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Cortés González JR, Garza R, Martínez R, Gómez L: [Prostate adenocarcinoma metastatic to penis]. Actas Urol Esp; 2006 Sep;30(8):832-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate adenocarcinoma metastatic to penis].
  • [Transliterated title] Adenocarcinoma de próstata metastático a pene.
  • Prostate cancer is a disease that appears with a very high frequency.
  • We present one case of a patient with painless metastatic nodules on the penis secondary to a prostate cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Urol Esp. 2006 Oct;30(9):962-4 [17175940.001]
  • (PMID = 17078582.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 6
  •  go-up   go-down


61. Mai KT, Nguyen B: Urothelial carcinoma and prostatic adenocarcinoma presenting as collision tumors. Can J Urol; 2009 Oct;16(5):4850-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma and prostatic adenocarcinoma presenting as collision tumors.
  • Urothelial carcinoma (UC) and prostatic adenocarcinoma (PAC) commonly occur in elderly patients and share common carcinogenic factors that could be identified in the urine.
  • Simultaneous occurrence of PAC and UC in the prostate is not uncommon; however, urinary bladder location of both lesions has not yet been reported.
  • All patients were diagnosed with high grade PAC and either had simultaneous at the initial diagnosis or developed UC during the follow up for PAC.
  • In conclusion, awareness of this association is important in making the correct diagnosis, especially when dealing with urinary bladder biopsy material.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biopsy. Combined Modality Therapy. Cystoscopy. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19796465.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


62. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A: Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr; 2005 May;135(5):989-95
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP).
  • Studies in vitro suggest that osteopontin (OPN), an extracellular matrix protein secreted by macrophages infiltrating prostate tumors, and by tumor cells, may have a role in the transition from clinically insignificant tumors to metastatic prostate cancer (PC).
  • Our earlier studies in TRAnsgenic Mouse Prostate adenocarcinoma (TRAMP) mice showed that genistein, an isoflavone found in soybeans, lowered the incidence of advanced PC.
  • Administration of 250 and 500 mg genistein/kg AIN-76A improved survival (P = 0.008 and P = 0.005, respectively) and reduced mean weight of prostates with poorly differentiated cancer (PD) (P < 0.001), as well as the mean weight of periaortic lymph nodes (LN), although the latter was not significant.
  • OPN mRNA levels in the dorsolateral prostate and metastasis to LN were significantly correlated (r = 0.643; P = 0.00006).
  • Genistein had a dose-dependent, significant inhibitory effect on OPN transcript levels in prostates displaying advanced prostate cancer (PD; score 6; P = 0.05).
  • [MeSH-major] Adenocarcinoma / genetics. Genistein / pharmacology. Prostatic Neoplasms / genetics. Sialoglycoproteins / genetics. Soybean Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867270.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 84926
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Sialoglycoproteins; 0 / Soybean Proteins; 0 / Spp1 protein, mouse; 106441-73-0 / Osteopontin; DH2M523P0H / Genistein
  •  go-up   go-down


63. Llarena Ibarguren R, García-Olaverri Rodríguez J, Villafruela Mateos A, Azurmendi Arin I, Olano Grasa I, Pertusa Peña C: [Metastases in the paranasal sinuses secondary to prostatic adenocarcinoma]. Arch Esp Urol; 2007 Nov;60(9):1.137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastases in the paranasal sinuses secondary to prostatic adenocarcinoma].
  • [Transliterated title] Metástasis en senos paranasales secundaria a adenocarcinoma prostático.
  • OBJECTIVE: To report a new case of exceptional metastases from a prostatic carcinoma.
  • METHODS: 64-year-old male with nine months history of disseminated prostate cancer, taking hormonal treatment and biphosphonates, who presents with rising PSA, facial dysesthesia and left exophtalmos.
  • RESULTS: Once the diagnosis was established hormonal maneuvers were performed and chemotherapy with docetaxel was administered achieving at the start of treatment measurable disease stabilization with biochemical remission of PSA levels, followed posteriorly by progression without changes in the metastatic images.
  • CONCLUSIONS: 1% of the prostatic tumors involve the head in their evolution.
  • [MeSH-major] Adenocarcinoma / secondary. Paranasal Sinus Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077874.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


64. Nassif AE, Tâmbara Filho R, Paula RX, Taguchi WS, Pozzobon HJ: [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment]. Rev Col Bras Cir; 2009 Aug;36(4):327-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment].
  • [Transliterated title] Perfil epidemiológico e fatores prognósticos no tratamento cirúrgico do adenocarcinoma de próstata clinicamente localizado.
  • OBJECTIVE: Radical prostatectomy remains the standard treatment for early prostate cancer.
  • METHODS: A total of 500 patients with prostate cancer underwent radical prostatectomy at Santa Rita hospital- Maringa-PR, between 2000 and 2006.
  • Clinical staging, preoperative prostate-specific antigen (PSA) and Gleason score were evaluated with pathological stage and margin status.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076923.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


65. Tohfe M, Baki SA, Saliba W, Ghandour F, Ashou R, Ghazal G, Bahous J, Chamseddine N: Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature. Cases J; 2008;1(1):316

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
  • INTRODUCTION: Prostate cancer has a high tendency to spread to bone.
  • Few patients with prostate cancer present initially with symptomatic metastatic lung lesions and lymphadenopathy without any other concomitant distant dissemination.
  • Despite the absence of any detectable osseous lesions and with the presence of multiple hilar, mediastinal, para-aortic, and pelvic lymphadenopathy, the patient had a complete work-up in search for the primary adenocarcinoma.
  • His prostate specific antigen was 146 ng/ml and a prostatic biopsy done, revealing an acinar prostatic adenocarcinoma.
  • A tru-cut biopsy of a lung lesion under computed tomography guidance showed a metastatic prostatic adenocarcinoma positive for prostate specific antigen stain.
  • CONCLUSION: This case sheds light on an unusual metastatic pattern of prostatic adenocarcinoma.
  • It also emphasizes the importance of including prostate cancer in the differential diagnosis of men with adenocarcinoma of unknown origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):216-9 [16678051.001]
  • [Cites] Urol Int. 1998 Oct;61(1):17-21 [9792977.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1843-6 [2317763.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • [Cites] Radiology. 1985 Mar;154(3):601-4 [2578678.001]
  • (PMID = 19014682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2590613
  •  go-up   go-down


66. Lefterov SI, Gorelov SI, Krivolapov IuA: [Prognostic significance of cell proliferation, microvascular density and androgen receptor level in prostatic adenocarcinoma]. Vopr Onkol; 2009;55(6):740-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of cell proliferation, microvascular density and androgen receptor level in prostatic adenocarcinoma].
  • Our study was concerned with prognostic significance of immunophenotypical features of prostate adenocarcinoma such as Ki-67 proliferation, androgen receptors (AR), microvascular density (MVD) in the stroma and tumor glands.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Neovascularization, Pathologic / metabolism. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Receptors, Androgen / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210018.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Androgen
  •  go-up   go-down


67. Chalasani V, Macek P, O'Neill GF, Barret W: Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma. Can J Urol; 2010 Feb;17(1):5031-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma.
  • This article describes an unusual finding in a patient who presented with an adenocarcinoma of the prostate and right hydronephrosis.
  • Cystoscopy showed an exophytic superficial transitional cell carcinoma (TCC) of the bladder and a transrectal biopsy of the prostate confirmed adenocarcinoma Gleason score 4+3.
  • Staging investigations (CT pelvis and bone scan) were negative; androgen deprivation therapy was therefore initiated for the prostatic adenocarcinoma.
  • With a working diagnosis of upper tract TCC, right open nephroureterectomy was performed.
  • Final histology showed prostatic adenocarcinoma infiltrating the adventitia of the entire ureter up to the level of the renal pelvis.
  • A rare cause of ureteric stricture, contiguous spread of prostatic adenocarcinoma, should be considered in the differential diagnosis of patients presenting with upper tract obstruction and a known history of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Ureter / pathology. Ureteral Obstruction / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156388.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


68. Bauduceau O, Vedrine L, Chargari C, Ceccaldi B, Le Moulec S, Houlgatte A: [Testicular metastasis of prostatic adenocarcinoma: a case report]. Prog Urol; 2007 Apr;17(2):251-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular metastasis of prostatic adenocarcinoma: a case report].
  • Metastasis of prostate adenocarcinoma to testis is an extremely rare occurrence.
  • Orchiectomy is necessary to confirm histopathological diagnosis.
  • Metastatic carcinoma of the prostate to the testis is a commonly accepted as a sign of disseminated disease.
  • We report a case of a 62-year-old patient who presented a prostatic carcinoma with a testicular metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489329.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


69. Lavasani L, Zapanta PE, Tanna N, Sadeghi N: Metastasis of prostatic adenocarcinoma to the sphenoid sinus. Ann Otol Rhinol Laryngol; 2006 Sep;115(9):690-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of prostatic adenocarcinoma to the sphenoid sinus.
  • The presentation, diagnosis, and management of prostatic adenocarcinoma metastatic to the sphenoid sinus are reviewed.
  • A 67-year-old man with a history of prostatic adenocarcinoma presented with gradual left visual loss.
  • Operative biopsy of the lesion was significant for adenocarcinoma of the prostate.
  • When an otolaryngologist encounters a mass in the sphenoid sinus, he or she needs to consider a diverse differential diagnosis.
  • As in this clinical scenario of a patient with a history of prostatic adenocarcinoma, appropriate analysis would entail sending specimens for immunohistochemical staining, such as prostate-specific antigen and prostate-specific acid phosphatase.
  • Correct diagnosis is crucial, as these patients may achieve remission and prolonged survival with irradiation and/or hormonal therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Paranasal Sinus Neoplasms / secondary. Prostatic Neoplasms / pathology. Sphenoid Sinus / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044541.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Taverna G, Colombo P, Seveso M, Giusti G, Piccinelli A, Benetti A, Graziotti P: Single small focus of prostate adenocarcinoma (&lt; or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy. Arch Ital Urol Androl; 2006 Jun;78(2):57-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy.
  • OBJECTIVES: To determine whether a clinical significant adenocarcinoma of the cinoma (defined as a lesion < or =1 mm. and too small for grading) at needle biopsy, even repeated, and through prostate specific antigen (PSA), PSA density (PSAD) and free-to-total PSA ratio (f/t ratio).
  • METHODS: Retrospectively 79/1610 consecutive patients undergoing prostatic needle biopsies presented one small focus of prostatic adenocarcinoma < or =1 mm and too small for grading.
  • All patients were submitted to radical retropubic prostatectomy (RRP) and were divided into three groups: group A (28/79 patients, 35.4%) submitted to RRP after diagnosis of just one small focus of adenocarcinoma at first biopsy; group B (26/79 patients, 32.9%) submitted to RRP after two successive diagnoses of small focus of adenocarcinoma; group C (25/79 patients, 31.6%) submitted to RRP after diagnosis of adenocarcinoma larger than 1 mm at successive biopsy in which Gleason score had been applied.
  • The aim of this retrospective study is to analyze the correlation between a single small focus of adenocarcinoma by prostatic biopsy, even repeated, and the clinical significant disease on the following radical retropubic prostatectomy.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929604.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


71. Madaan S, Palit V, Gudgeon P, Biyani CS: Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma. Can Urol Assoc J; 2007 Sep;1(3):288-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma.
  • Omental metastasis with malignant ascites from prostatic adenocarcinoma is rare.
  • Clinical examination revealed a hard prostate and blood biochemistry demonstrated an elevated prostate specific antigen level.
  • A Doppler ultrasound scan excluded deep venous thrombosis, but a CT scan of the abdomen revealed marked para-aortic lymphadenopathy and prostate gland biopsy confirmed prostatic adenocarcinoma.
  • Histology of the omental mass showed metastasis from the prostatic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1992 May;39(5):495-7 [1580050.001]
  • [Cites] Lymphology. 1990 Dec;23(4):183-6 [2077299.001]
  • [Cites] J Urol. 1973 Aug;110(2):232-4 [4722620.001]
  • [Cites] Urology. 2002 May;59(5):773 [11992926.001]
  • [Cites] Am J Med Sci. 2004 May;327(5):262-3 [15166746.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(3):225-7 [12201941.001]
  • [Cites] Am J Med. 2001 Aug 15;111(3):245-6 [11545100.001]
  • [Cites] J Urol. 1968 Aug;100(2):183-7 [5658662.001]
  • (PMID = 18542809.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2422958
  •  go-up   go-down


72. Bai AS, Zeng H, Li X, Wei Q, Li H, Yang YR: [Expression of kinase insert domain-containing receptor in prostate adenocarcinoma]. Zhonghua Nan Ke Xue; 2007 Apr;13(4):324-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of kinase insert domain-containing receptor in prostate adenocarcinoma].
  • OBJECTIVE: To investigate the correlation between the expression of the kinase insert domain-containing receptor (KDR) and the histological grade of prostate adenocarcinoma.
  • METHODS: Forty-eight samples of prostate adenocarcinoma tissues and 20 samples of benign prostatic hypertrophy (BPH) tissues were studied by LsAB immunohistochemical staining.
  • RESULTS: The positive expression rate of KDR was 73% in prostate adenocarcinoma and 30% in BPH.
  • The expression of KDR was stronger in prostate adenocarcinoma, and there was no relationship between staining intensity and the histological grade of carcinoma.
  • CONCLUSION: KDR, expressed more highly in prostate adenocarcinoma, promises to be a new target in the treatment of prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Vascular Endothelial Growth Factor Receptor-2 / biosynthesis

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491265.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


73. Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, Brassell SA: Clinicopathological behavior of single focus prostate adenocarcinoma. J Urol; 2009 Dec;182(6):2689-94
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological behavior of single focus prostate adenocarcinoma.
  • PURPOSE: With the increasing use of focal therapy for prostate adenocarcinoma a pathological basis for its appropriate application must be established.
  • We determined the clinicopathological characteristics and natural history of single focus prostate cancer since this entity seems to be the ideal target for focal therapy.
  • MATERIALS AND METHODS: We queried the Center for Prostate Disease Research database for all patients who underwent radical prostatectomy at Walter Reed Army Medical Center from 1993 through 2008.
  • Patients with single focus prostate adenocarcinoma were compared with those who had multifocal disease.
  • CONCLUSIONS: Single focus prostate cancer appears to have more aggressive behavior than multifocal disease.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836800.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Kim HS, Sung W, Lee S, Chang SG, Park YK: Lymphatic vessel densities of lymph node-negative prostate adenocarcinoma in Korea. Pathol Res Pract; 2009;205(4):249-54
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel densities of lymph node-negative prostate adenocarcinoma in Korea.
  • Although lymphatic vessel density (LVD) is associated with regional lymph node (LN) metastasis in prostate adenocarcinoma, no study is available that examines whether the LVD is correlated with prognostic factors other than LN metastasis in LN-negative prostate adenocarcinoma.
  • The aim of our study was to analyze intratumoral (IT), peritumoral (PT), and nontumoral (NT) LVDs, and to determine if there is a correlation between the LVD and the clinicopathological parameters in the Korean LN-negative prostate adenocarcinoma patients.
  • The IT-LVD was significantly lower in patients with larger tumor volume (P=0.029) and higher preoperative prostate-specific antigen level (P=0.008).
  • Our results suggest that IT- and PT-LVDs may increase in LN-negative prostate adenocarcinoma as a result of lymphangiogenesis, but IT lymphatics may decrease due to mechanical compression and destruction caused by proliferating tumor cells.
  • In addition, IT-LVD may be used as a prognostic factor in LN-negative prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphangiogenesis. Lymphatic Vessels / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Korea. Lymph Nodes / pathology. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058917.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


75. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology; 2007 Mar;50(4):472-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.
  • AIMS: To determine prostate-specific membrane antigen (PSMA) expression in normal tissues and in 3161 benign and malignant tumours and subsequently to define its sensitivity and specificity in prostatic adenocarcinoma (PaC).
  • Furthermore, its sensitivity and specificity in differentiating PaC from urothelial cancer is 65.9% and 82.9%, respectively.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Female. Humans. Immunohistochemistry. Male. Organ Specificity. Prostate / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / metabolism. Reference Values. Sensitivity and Specificity. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448023.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Surface; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


76. Svatek RS, Karam JA, Rogers TE, Shulman MJ, Margulis V, Benaim EA: Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens. Prostate Cancer Prostatic Dis; 2007;10(3):279-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens.
  • Prostatic crystalloids are intraluminal eosinophilic structures with variable size and shape.
  • Their presence has been described in conjunction with the occurrence of prostatic adenocarcinoma (pCA).
  • We herein report the association of crystalloids and pCA in a prospective trial utilizing an extended multi-site transrectal ultrasound-guided (TRUS) prostate biopsy protocol.
  • Indications for biopsy included a prostate-specific antigen (PSA) > or =4 ng/ml and/or abnormal digital rectal exam.
  • Overall cancer detection rate was 42.7%.
  • pCA was diagnosed in 66 (81.5%) of 81 patients with crystalloids, 70 (69.3%) of 101 patients with high-grade prostatic intraepithelial neoplasia (HGPIN), and 32 (84.2%) of 38 patients with both HGPIN and crystalloids on biopsy.
  • Multivariate analysis identified crystalloids (RR 4.53, 95% CI 2.30-8.88) and HGPIN (RR 3.20, 95% CI 1.84-5.57) as independent predictors of the presence of cancer on concurrent biopsy (P<0.001).
  • These findings suggest that the presence of crystalloids alone or in combination with HGPIN in prostate biopsies may be a more compelling indication for repeat biopsy than HGPIN alone.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor. Inclusion Bodies / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325718.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Urbanskiĭ AI, Shkol'nik MI, Zhivov AV, Plekhanov AIu, Galanin SV, Strokova LA, Khalimdzhanov ZK: [The frequency and diagnostic value of microscopic signs of minimal prostate adenocarcinoma]. Arkh Patol; 2006 Nov-Dec;68(6):25-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The frequency and diagnostic value of microscopic signs of minimal prostate adenocarcinoma].
  • Prostate biopsy specimens from 64 patients were studied.
  • In most cases with minimal prostate adenocarcinoma, the tumor was limited by the organ and of moderate malignancy.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290889.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


78. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom M, Widmark A, Stattin P: Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol; 2007;41(6):456-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
  • OBJECTIVE: The incidence of prostate cancer is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, tumor characteristics and treatment.
  • MATERIAL AND METHODS: Between 1996 and 2005, all new cases of adenocarcinoma of the prostate gland were intended to be registered in the National Prostate Cancer Register (NPCR).
  • This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, tumor grade, tumor stage according to the TNM classification in force, serum prostate-specific antigen (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis.
  • RESULTS: In total, 72,028 patients were registered, comprising >97% of all pertinent incident cases of prostate cancer in the Swedish Cancer Register (SCR).
  • During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller tumors, a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of men diagnosed with distant metastases or with a PSA level of > 100 ng/ml at diagnosis and an increase in the proportion of tumors with Gleason score <6.
  • Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c tumors were observed.
  • In men with localized tumors and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged > or =75 years than in those aged <75 years.
  • The patterns of diagnosis and treatment of prostate cancer vary considerably in different parts of Sweden.
  • The NPCR continues to be an important source for research, epidemiological surveillance of the incidence, diagnosis and treatment of prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. Registries. Retrospective Studies. Sweden

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17934985.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


79. Marcu M, Radu E, Sajin M: Neuroendocrine differentiation in prostate adenocarcinoma biopsies and its correlation to histological grading. Curr Health Sci J; 2010 Jan;36(1):37-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine differentiation in prostate adenocarcinoma biopsies and its correlation to histological grading.
  • Prostate adenocarcinoma is frequently diagnosed on needle biopsies in early, organ-confined stages.
  • This study aims to find correlations between the extent of neurocrine differentiation (NED), a feature commonly seen in prostate carcinoma, and known factors of disease evolution such as histological grade, malignant cell proliferation and serum PSA levels.
  • Immunohistochemistry for choromogranin A and neuron-specific enaolase (NSE) was used to calculate expression scores in order to asses the extent of NED in prostate biopsies.
  • Multinomial regression analysis showed that high Ki indices, serum PSA values and NSE scores are predictive for moderately and poorly differentiated prostatic adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24778825.001).
  • [ISSN] 2067-0656
  • [Journal-full-title] Current health sciences journal
  • [ISO-abbreviation] Curr Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3945267
  • [Keywords] NOTNLM ; Neuroendocrine differentiation / Prostate adenocarcinoma
  •  go-up   go-down


80. Rabien A, Fritzsche F, Jung M, Diamandis EP, Loening SA, Dietel M, Jung K, Stephan C, Kristiansen G: High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Tumour Biol; 2008;29(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
  • OBJECTIVE: Reliable prognostic tools for prostate cancer are still needed and KLK14, a young member of the growing family of human kallikrein-related peptidases, has been estimated to become a new significant marker.
  • It is the aim of this study to analyze the clinical value of immunohistochemical expression of KLK14 in prostate cancer tissue samples.
  • Areas of normal prostatic tissue, of prostatic epithelial neoplasia and of prostatic adenocarcinoma were checked in relation to clinicopathological parameters of the patients.
  • Expression of KLK14 mRNA was quantified in 25 matches of normal and cancerous prostatic tissue, collected by laser capture microdissection.
  • RESULTS: Expression of the KLK14 protein correlated with the pathological tumor status in prostate cancer and was associated with disease progression defined by prostate-specific antigen relapse in univariate Kaplan-Meier analysis.
  • The multivariate Cox proportional hazards regression model proved KLK14 to be an independent prognostic factor in prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Kallikreins / genetics. Prostate-Specific Antigen / blood. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18497543.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.21.- / KLK14 protein, human; EC 3.4.21.- / Kallikreins; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


81. Park PC, Mai KT, Roustan Delatour NL, Morash C, Cagiannos I: Predictive value of prostatic adenocarcinoma after a negative prostate biopsy. BJU Int; 2006 Nov;98(5):986-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of prostatic adenocarcinoma after a negative prostate biopsy.
  • OBJECTIVE: To investigate the predictive value (PV) for all prostate cancers and for clinically significant cancer undiagnosed after a 10-core biopsy protocol, as the 10-core transrectal ultrasonography-guided biopsy is considered the standard technique of prostatic biopsy due to its high rate of detection of prostatic adenocarcinoma.
  • Cases with unilateral core involvement by prostate cancer were retained for study.
  • RESULTS: In all, 70 resected prostates (RP) had unilateral core involvement by prostate cancer.
  • In 38 cases, there was cancer in the biopsy-negative hemi-prostates (group 1); in the remaining 32 the hemi-prostates were free of cancer (group 2).
  • Specifically, 23 cases had one to eight foci of prostate cancer in the posterior nontransitional zone (NTZ) (group 1a), while 15 had two to six foci of prostate cancer in the transitional zone (TZ), or the anterior horn (AH) of the peripheral zone or the TZ and AH (group 1b).
  • There were two cases with clinically significant prostate cancer in group 1a, and six in group 1b.
  • CONCLUSIONS: The PV of a negative five-core biopsy protocol on a hemi-prostate is 54% for prostate cancer and 11% for clinically significant prostate cancer.
  • Most clinically significant prostate cancers were in the AH/TZ of the prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Humans. Male. Middle Aged. Predictive Value of Tests. Prostate-Specific Antigen / blood. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034600.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


82. O'Connor JK, Nedzi LA, Zakris EL: Prostate adenocarcinoma and human immunodeficiency virus: report of three cases and review of the literature. Clin Genitourin Cancer; 2006 Jun;5(1):85-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate adenocarcinoma and human immunodeficiency virus: report of three cases and review of the literature.
  • EBRT) in patients with prostate adenocarcinoma and HIV and to review the published literature for this population.
  • Three patients with prostate adenocarcinoma and HIV were treated with definitive RT.
  • Medical records were reviewed for prostate cancer and HIV characteristics, RT details, and acute toxicity.
  • All 3 patients had excellent acute tolerance to definitive EBRT and, with short follow-up, all had decreasing prostate-specific antigen levels.
  • The published literature regarding patients with prostate adenocarcinoma and HIV is scarce but suggests that men with HIV might be at higher risk of developing prostate cancer.
  • All 3 patients with prostate adenocarcinoma and HIV had an excellent acute tolerance to EBRT.
  • Prostate cancer is expected to become an increasingly important health problem for men infected with HIV as their life expectancy lengthens.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / radiotherapy. HIV Infections / complications. Prostatic Neoplasms / complications. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16859585.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


83. Kruslin B, Tomas D, Rogatsch H, Reljić A, Vucić M, Balicević D, Belicza M, Mikuz G: Correlation of periacinar retraction clefting in needle core biopsies and corresponding prostatectomy specimens of patients with prostatic adenocarcinoma. Int J Surg Pathol; 2005 Jan;13(1):67-72
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of periacinar retraction clefting in needle core biopsies and corresponding prostatectomy specimens of patients with prostatic adenocarcinoma.
  • One of the underemphasized supportive criteria for the diagnosis of prostatic cancer is the presence of retraction clefting around neoplastic glands.
  • We analyzed a series of 152 prostatic cancer cases to determine the frequency, extent, and correlation of periacinar retraction clefting between needle core biopsies (NCB) and corresponding matched radical prostatectomy (RP) specimens.
  • We conclude that periacinar retraction clefting appears more frequently in neoplastic acini and could serve as a reliable criterion in the diagnosis of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle. Prostate / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735857.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Kwon YW, Chang IH, Kim KD, Kim YS, Myung SC, Kim MK, Kim TH: Significance of S100A2 and S100A4 Expression in the Progression of Prostate Adenocarcinoma. Korean J Urol; 2010 Jul;51(7):456-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of S100A2 and S100A4 Expression in the Progression of Prostate Adenocarcinoma.
  • We also sought to determine the prognostic value of these markers for patients with prostate adenocarcinoma.
  • MATERIALS AND METHODS: Immunohistochemical staining was performed to detect S100A2 and S100A4 expression in 26 tissue samples obtained during transurethral resection from patients with benign prostatic hyperplasia (BPH) and in 67 tissue samples obtained during prostate biopsy and radical prostatectomy from patients with prostate carcinoma.
  • The immunoreactivity of these proteins was stratified on a scale of 0 to 3 and was correlated with the pathologic features of prostate adenocarcinoma.
  • RESULTS: High expression of S100A2 was observed in the tissue of patients with BPH, whereas low or no expression was observed in prostate cancer (CaP) cells.
  • The simultaneous analysis of S100A2 and S100A4 expression in prostate tissues may be a useful prognostic marker for CaP.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):217-27 [16492908.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):677-80 [16243835.001]
  • [Cites] FEBS Lett. 1999 Feb 26;445(2-3):265-8 [10094469.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2309-16 [9815629.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 10;1448(2):190-9 [9920410.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2415-21 [9703888.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):464-9 [9291441.001]
  • [Cites] Trends Biochem Sci. 1996 Apr;21(4):134-40 [8701470.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] Gene. 1993 Dec 15;135(1-2):229-38 [8276262.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2504-8 [1372446.001]
  • [Cites] Biochem Biophys Res Commun. 1965 Jun 9;19(6):739-44 [4953930.001]
  • [Cites] Curr Opin Urol. 2004 May;14(3):143-9 [15069304.001]
  • [Cites] Methods Mol Biol. 2002;172:69-80 [11833360.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):123-30 [11813862.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):409-16 [11875708.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7999-8004 [11691825.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):707-12 [11510959.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 [11390274.001]
  • [Cites] Lab Invest. 2001 Apr;81(4):599-612 [11304580.001]
  • [Cites] Histol Histopathol. 2000 Oct;15(4):1271-84 [11005251.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1473-9 [11076656.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):345-9 [10956408.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1595-603 [10749128.001]
  • (PMID = 20664777.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2907493
  • [Keywords] NOTNLM ; Prostatic hyperplasia / Prostatic neoplasms / S100A2 protein, human / S100A4 protein, human
  •  go-up   go-down


85. Xiao GQ, Burstein DE, Miller LK, Unger PD: Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Jun;130(6):805-10
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic carcinoma, particularly when dealing with lesions from the prostatic urethra.
  • OBJECTIVE: To elucidate a possible histogenic relationship between nephrogenic adenoma and renal tubules, and also to evaluate the role of immunohistochemistry in the diagnostic distinction between nephrogenic adenoma and prostate carcinoma.
  • DESIGN: Immunohistochemical studies were performed for P504S, prostate-specific antigen, CD10, p63, and epithelial membrane antigen on 9 cases of nephrogenic adenoma, 10 cases of normal renal parenchyma, and 10 cases of prostatic tissue, both benign and malignant.
  • RESULTS: Nephrogenic adenoma shares the same immunohistochemical profile as distal renal tubules: both are positive for P504S and epithelial membrane antigen and negative for p63, CD10, and prostate-specific antigen.
  • Prostatic adenocarcinoma tissue was positive for P504S and prostate-specific antigen, and normal prostatic gland tissue was positive for prostate-specific antigen and negative for P504S; p63-stained basal cells in normal prostatic gland tissue but did not react with prostatic adenocarcinoma tissue.
  • The CD10 inconsistently stained normal and neoplastic prostatic gland tissue.
  • Epithelial membrane antigen stain was negative in prostatic carcinoma, with rare occasional reactivity in normal prostatic glands.
  • Our results also demonstrated that the combination of P504S and prostate-specific antigen with epithelial membrane antigen is a valuable tool in distinguishing prostatic carcinoma from nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Immunohistochemistry / methods. Prostatic Neoplasms / diagnosis. Urologic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Mucin-1 / analysis. Racemases and Epimerases / analysis. Urothelium / chemistry. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740031.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


86. Epstein JI: Precursor lesions to prostatic adenocarcinoma. Virchows Arch; 2009 Jan;454(1):1-16
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lesions to prostatic adenocarcinoma.
  • High-grade prostatic intraepithelial neoplasia (PIN) is the one well-documented precursor to adenocarcinoma of the prostate.
  • High-grade PIN is also differentiated from invasive acinar (usual) and ductal adenocarcinoma.
  • The incidence of high-grade PIN, its relationship to carcinoma (including molecular findings), and risk of cancer on rebiopsy are covered in detail.
  • Finally, intraductal carcinoma of the prostate, a controversial entity, is discussed and differentiated from high-grade PIN.
  • [MeSH-major] Adenocarcinoma / pathology. Precancerous Conditions / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / pathology. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):437-9 [16567473.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):929-33; discussion 933 [16469583.001]
  • [Cites] Urology. 1995 Dec;46(6):837-42 [7502426.001]
  • [Cites] Urology. 1997 Apr;49(4):558-63 [9111625.001]
  • [Cites] Eur Urol. 1999;35(5-6):474-8 [10325508.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1534-9 [11717544.001]
  • [Cites] J Urol. 2006 Jan;175(1):121-4 [16406886.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):140-4 [10632499.001]
  • [Cites] Urology. 2004 Mar;63(3):503-8 [15028446.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):808-11 [9399656.001]
  • [Cites] BJU Int. 2007 Apr;99(4):765-9 [17378840.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):644-52 [1712748.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):292-7 [16613324.001]
  • [Cites] Prostate. 2000 Apr 1;43(1):11-9 [10725861.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(1):20-31 [17909565.001]
  • [Cites] Hum Pathol. 2002 May;33(5):518-23 [12094377.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Cancer. 1969 Jan;23(1):24-34 [5763258.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Urology. 2006 Oct;68(4):800-3 [17070356.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Urology. 2007 Dec;70(6):1100-3 [18158026.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1291-6 [11283929.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):742-51 [8832557.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):389-91 [9458077.001]
  • [Cites] J Urol. 2000 Mar;163(3):819-23 [10687984.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):873-86 [7611534.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1184-8 [16931964.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • [Cites] Am J Surg Pathol. 1986 Oct;10(10):665-71 [3766845.001]
  • [Cites] Cancer Lett. 1999 Jul 1;141(1-2):173-8 [10454259.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1060-7 [18496142.001]
  • [Cites] J Urol. 1997 Jul;158(1):12-22 [9186314.001]
  • [Cites] Hum Pathol. 2005 May;36(5):480-5 [15948114.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):802-14 [8669528.001]
  • [Cites] BJU Int. 2007 Apr;99(4):770-4 [17233800.001]
  • [Cites] BJU Int. 2004 Sep;94(4):528-33 [15329106.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1415-8 [12352407.001]
  • [Cites] Urology. 2005 Apr;65(4):745-9 [15833520.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1215-22 [9331295.001]
  • [Cites] Urology. 1997 Sep;50(3):355-9 [9301697.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):435-40 [9130990.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):899-906 [16607376.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1714-9 [3756794.001]
  • [Cites] Urology. 2001 Dec;58(6):999-1003 [11744476.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] J Urol. 2008 May;179(5):1751-5; discussion 1755 [18343427.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2617-22 [18451224.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):967-71 [10487854.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):267-74 [15586249.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1528-35 [16980940.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Prostate. 1996 Aug;29(2):117-34 [8700801.001]
  • [Cites] Neoplasia. 2006 Oct;8(10 ):826-32 [17032499.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Int Urol Nephrol. 2007;39(1):189-95 [16835725.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3966-71 [8508361.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1390-4; discussion 1394; author reply 1394 [16145444.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):147-55 [11176063.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Can J Urol. 2006 Oct;13(5):3255-60 [17076947.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • (PMID = 19048290.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 85
  •  go-up   go-down


87. Xiao GQ, Huan Y, Stone N, Stock R, Unger PD: Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy. Pathol Res Pract; 2009;205(12):843-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy.
  • A total of 60 patients with prostatic adenocarcinoma treated with brachytherapy between 1993 and 2003, who had at least one positive post-radiation biopsy, were evaluated for their morphologic patterns as well as the associated PSA levels.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Neoplasm Recurrence, Local. Prostate-Specific Antigen / blood. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646822.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


88. Lotan TL, Epstein JI: Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol; 2009 Apr;40(4):471-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy.
  • Glomerulations in prostatic adenocarcinoma are characterized by dilated glands containing intraluminal cribriform structures with a single point of attachment, resembling a renal glomerulus.
  • On prostate biopsy, glomerulations are exclusively associated with carcinoma and not associated with benign mimickers.
  • We prospectively collected 45 prostate needle biopsies containing carcinoma with glomeruloid features from our consult files for a 9-month period and examined the association between glomerulations and the presence of concurrent high-grade carcinoma.
  • Glomerulations were overwhelmingly associated with high-grade cancer on the same core, composed of either Gleason pattern 4 (n = 36, 80% of cases) or Gleason pattern 5 (n = 2, 4% of cases).
  • Only a minority of glomerulations were surrounded exclusively by pattern 3 cancer (n = 7, 16% of cases) on the same core.
  • Most of the cases with surrounding pattern 4 cancer were scored as 3 + 4 = 7 (n = 24, 66%), whereas a smaller fraction were scored as 4 + 3 = 7 (n = 9, 26%), and only a minority were 4 + 4 = 8 (n = 3, 9%).
  • Glomeruloid structures are a rare but diagnostic feature of prostatic carcinoma on needle biopsy.
  • In several cases, transition could be seen among small glomerulations, large glomeruloid structures, and cribriform pattern 4 cancer.
  • These data suggest that glomerulations represent an early stage of cribriform pattern 4 cancer and, until follow-up data are available, are best graded as Gleason pattern 4.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):125-8 [5948714.001]
  • [Cites] Hum Pathol. 1998 May;29(5):543-6 [9596281.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):543-51 [9647592.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1532-9 [18724248.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):57-9 [16462155.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):292-7 [16613324.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):35-42 [17213347.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):918-24 [10435561.001]
  • (PMID = 19128819.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058236
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS403689; NLM/ PMC3484379
  •  go-up   go-down


89. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R: Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors; 2010 Dec 31;2(4):e65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple urinary bladder masses from metastatic prostate adenocarcinoma.
  • We present an unusual case of metastatic prostate adenocarcinoma that manifested with multiple exophytic intravesical masses, mimicking a multifocal primary bladder tumor.
  • Biopsy with immunohistochemical analysis confirmed metastatic prostate adenocarcinoma.
  • This case illustrates that when a patient with known prostate cancer presents with multifocal bladder tumors, the possibility of metastatic prostate cancer should be considered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Jan;36(1):32-40 [10632749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):379-88 [10802363.001]
  • [Cites] Hinyokika Kiyo. 2001 Oct;47(10):747-9 [11758360.001]
  • [Cites] J Urol. 1955 Oct;74(4):498-521 [13264313.001]
  • [Cites] J Urol. 2005 Dec;174(6):2186-90 [16280761.001]
  • [Cites] J Natl Cancer Inst. 2009 Sep 16;101(18):1280-3 [19713548.001]
  • [Cites] Hinyokika Kiyo. 2010 Feb;56(2):123-5 [20186001.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Urol Int. 1994;53(1):50-2 [7974888.001]
  • [Cites] Ann Diagn Pathol. 2007 Dec;11(6):413-6 [18022125.001]
  • [Cites] Lancet. 2009 Jan 24;373(9660):301-8 [19091394.001]
  • [Cites] Radiother Oncol. 2009 Nov;93(2):192-6 [19464745.001]
  • (PMID = 21234257.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019600
  • [Keywords] NOTNLM ; prostatic neoplasms / radiotherapy. / urinary bladder neoplasms
  •  go-up   go-down


90. Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, Acquafondata M, Pflug BR: Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol; 2006 Apr;37(4):401-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma.
  • Cancer cells frequently exhibit a significant increase in overexpression and activity of fatty acid synthase (FASN).
  • Elevated FASN pathway activity also occurs in prostate cancer, the second leading cause of cancer-related death in men in the United States.
  • Studies show that genes associated with an increase in protein expression, such as HER2/neu in breast cancer, are associated with an increase in gene copy number as well as an increase in transcription.
  • In the present study, we evaluated whether FASN follows a similar paradigm in prostate cancer.
  • To date, elevated FASN expression in prostate cancer has not been correlated with gene copy number alterations.
  • Using immunohistochemistry and fluorescence in situ hybridization analysis in paraffin-embedded tissue microarrays, we observed gene copy gain in 24% of all prostate adenocarcinoma specimens examined with concurrent increased FASN protein expression.
  • Immunohistochemistry alone showed 59% of prostate cancer specimens in the same tissue microarray with high FASN expression.
  • Increased FASN gene was observed in 53% of all prostate tissues expressing elevated FASN protein levels and in 2 of 5 prostate tumor cell lines tested.
  • These findings suggest that FASN gene copy number increases may be involved in the resultant increase in FASN protein expression observed in prostatic disease.
  • [MeSH-major] Adenocarcinoma / genetics. Fatty Acid Synthases / genetics. Gene Dosage. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564913.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA095239
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.3.1.85 / Fatty Acid Synthases
  •  go-up   go-down


91. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol; 2007 Feb;211(3):269-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
  • Promoter CpG island hypermethylation is an important carcinogenic event in prostate adenocarcinoma.
  • The present study evaluated CpG island loci hypermethylation and LINE-1 and Alu repeat hypomethylation in prostate adenocarcinoma, analysed the relationship between them, and correlated these findings with clinicopathological features.
  • We examined 179 cases of prostate adenocarcinoma and 30 cases of benign prostate hypertrophy for the methylation status of 22 CpG island loci and the methylation levels of LINE-1 and Alu repeats using methylation-specific polymerase chain reaction and combined bisulphite restriction analysis, respectively.
  • The following 16 CpG island loci were found to display cancer-related hypermethylation: RASSF1A, GSTP1, RARB, TNFRSF10C, APC, BCL2, MDR1, ASC, TIG1, RBP1, COX2, THBS1, TNFRSF10D, CD44, p16, and RUNX3.
  • Except for the last four CpG island loci, hypermethylation of each of the remaining 12 CpG island loci displayed a close association with one or more of the prognostic parameters (ie preoperative serum prostate specific antigen level, Gleason score sum, and clinical stage).
  • Prostate adenocarcinoma with hypermethylation of each of ASC, COX2, RARB, TNFRSF10C, MDR1, TIG1, RBP1, NEUROG1, RASSF1A, and GSTP1 showed a significantly lower methylation level of Alu or LINE-1 than prostate adenocarcinoma without hypermethylation.
  • These data suggest that in tumour progression a close relationship exists between CpG island hypermethylation and the hypomethylation of repetitive elements, and that CpG island hypermethylation and DNA hypomethylation contribute to cancer progression.
  • [MeSH-major] Adenocarcinoma / metabolism. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Promoter Regions, Genetic. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Alu Elements / genetics. DNA / analysis. Humans. Long Interspersed Nucleotide Elements / genetics. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Prognosis. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / metabolism. Repetitive Sequences, Nucleic Acid


92. Tsujino K, Sasada S, Kawahara K, Terada H, Komori C, Suzuki H, Okamoto N, Kobayashi M, Hirashima T, Matsui K, Kawase I: [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy]. Nihon Kokyuki Gakkai Zasshi; 2007 Aug;45(8):648-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy].
  • We report a 70-year-old man with prostatic carcinoma presenting as supraclaviculer and mediastinal lymphadenopathy.
  • He had no urinary tract symptoms, and computed tomography and FDG-PET showed no abnormality in the prostate or pelvic lymph nodes.
  • Metastatic prostatic adenocarcinoma was finally diagnosed from the results of immunohistochemical staining for PSA of a biopsy specimen of the mediastinal lymph node, and he was treated by hormonal therapy.
  • There are fears that some other similar cases might be treated with chemotherapy as lung cancer without immunohistochemical staining.
  • Prostatic carcinoma should always be considered in the differential diagnosis of elderly men with supraclaviculer or mediastinal lymph node metastases, since appropriate treatment will lead to a prolonged survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymph Nodes / pathology. Lymphatic Diseases / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Needle. Humans. Lymphatic Metastasis. Male. Mediastinum. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763696.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


93. Hameed O, Humphrey PA: Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol; 2006 Jul;19(7):899-906
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
  • Typically glands of prostatic adenocarcinoma have a single cell lining, although stratification can be seen in invasive carcinomas with a cribriform architecture, including ductal carcinoma.
  • The presence and diagnostic significance of stratified cells within non-cribriform carcinomatous prostatic glands has not been well addressed.
  • The histomorphological features and immunohistochemical profile of cases of non-cribriform prostatic adenocarcinoma with stratified malignant glandular epithelium were analyzed.
  • These cases were identified from needle biopsy cases from the consultation files of one of the authors and from a review of 150 consecutive in-house needle biopsy cases of prostatic adenocarcinoma.
  • The main attribute in all these foci was the presence of glandular profiles lined by several layers of epithelial cells with cytological and architectural features resembling flat or tufted high-grade prostatic intraepithelial neoplasia, but lacking basal cells as confirmed by negative 34betaE12 and/or p63 immunostains in all cases.
  • The AMACR staining profile of the stratified foci was variable, with 4 foci showing positivity, and 3 foci being negative, including two cases that displayed AMACR positivity in adjacent non-stratified prostatic adenocarcinoma.
  • Prostatic adenocarcinoma with stratified malignant glandular epithelium can be identified in prostate needle biopsy samples harboring non-cribriform prostatic adenocarcinoma and resembles glands with high-grade prostatic intraepithelial neoplasia.
  • Recognition of this pattern of prostatic adenocarcinoma is necessary to correctly diagnose such cases as invasive carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Epithelium / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Invasiveness. Prostate-Specific Antigen / blood. Racemases and Epimerases / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607376.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


94. Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE: Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem; 2009 Aug 1;107(5):992-1001
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression.
  • Prostate tumorigenesis is associated with loss of PTEN gene expression.
  • Herein, we tested the hypothesis that alterations of the Notch-1 signaling pathway are present in human prostate adenocarcinoma and that Notch-1 signaling regulates PTEN gene expression in prostate cells.
  • Prostate adenocarcinoma cases were examined by immunohistochemistry for ligand cleaved (activated) Notch-1 protein.
  • Reduced Hey-1 expression was seen in tumor foci but not in benign tissue, confirming loss of Notch-1 signaling in prostate adenocarcinoma.
  • Retroviral expression of constitutively active Notch-1 in human prostate tumor cell lines resulted in increased PTEN gene expression.
  • Incubation of prostate cell lines with the Notch-1 ligand, Delta, resulted in increased PTEN expression indicating that endogenous Notch-1 regulates PTEN gene expression.
  • These data collectively indicate that defects in Notch-1 signaling may play a role in human prostate tumor formation in part via a mechanism that involves regulation of the PTEN tumor suppressor gene.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. PTEN Phosphohydrolase / genetics. Prostatic Neoplasms / enzymology. Prostatic Neoplasms / genetics. Receptors, Notch / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19479935.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / RBPJ protein, human; 0 / Receptors, Notch; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


95. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R: Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol; 2006 Nov;169(5):1812-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma.
  • In prostate adenocarcinoma, 39 microRNAs are up-regulated, and six microRNAs are down-regulated.
  • From a gene array analysis of 16 normal prostate tissue samples, 64 organ-confined, and four metastatic prostate adenocarcinomas, we identified an up-regulation of major components of the microRNA machinery, including Dicer, in metastatic prostate adenocarcinoma.
  • Immunohistochemical studies on a tissue microarray consisting of 232 prostate specimens confirmed up-regulation of Dicer in prostatic intraepithelial neoplasia and in 81% of prostate adenocarcinoma.
  • The increased Dicer level in prostate adenocarcinoma correlated with clinical stage, lymph node status, and Gleason score.
  • Western blot analysis of benign and neoplastic prostate cell lines further confirmed Dicer up-regulation in prostate adenocarcinoma.
  • Dicer up-regulation may explain an almost global increase of microRNA expression in prostate adenocarcinoma.
  • The presence of up-regulated microRNA machinery may predict the susceptibility of prostate adenocarcinoma to RNA interference-based therapy.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. DEAD-box RNA Helicases / metabolism. Endoribonucleases / metabolism. MicroRNAs / metabolism. Prostatic Neoplasms / enzymology. Prostatic Neoplasms / pathology. Up-Regulation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Epithelium / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Microarray Analysis. Middle Aged. Prostate / cytology. Prostate / enzymology. Prostate / pathology. Ribonuclease III

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2004 Aug;6(8):784-91 [15247924.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):552-4 [14697225.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3011-6 [14681208.001]
  • [Cites] Nat Neurosci. 2004 Feb;7(2):113-7 [14703574.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):1425-35 [14699070.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 1996;30(2):201-5 [8875201.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1215-23 [9214605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 [9465086.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1048-53 [15516998.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Cell. 2005 Jan 14;120(1):21-4 [15652478.001]
  • [Cites] Cancer Gene Ther. 2005 Mar;12(3):217-27 [15550938.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):111-5 [15723655.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Biochem J. 2005 May 1;387(Pt 3):561-71 [15845026.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3509-12 [15867338.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Curr Opin Struct Biol. 2005 Jun;15(3):331-41 [15925505.001]
  • [Cites] BMC Cancer. 2005;5:45 [15892885.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] J Exp Med. 2005 Jul 18;202(2):261-9 [16009718.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):740-4 [15973356.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Eur Urol. 2005 Nov;48(5):852-7 [16230228.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):688-93 [16271080.001]
  • [Cites] Cancer Gene Ther. 2005 Dec;12(12):926-34 [15956982.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Curr Biol. 2005 Dec 6;15(23):2149-55 [16289642.001]
  • [Cites] Differentiation. 2005 Dec;73(9-10):463-73 [16351690.001]
  • [Cites] Genes Dev. 2005 Dec 15;19(24):2979-90 [16357216.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):4-9 [16361094.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):179-86 [16432177.001]
  • [Cites] EMBO J. 2006 Feb 8;25(3):522-32 [16424907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):776-80 [16495913.001]
  • [Cites] Genome Biol. 2006;7(3):210 [16584538.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2056-60 [12154197.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Prostate. 2002 May 1;51(2):98-107 [11948964.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):177-81 [12127403.001]
  • [Cites] Chin Med J (Engl). 2002 Apr;115(4):571-5 [12133301.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1833-7 [12193640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16648-53 [12482946.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] Urology. 2003 Aug;62(2):378-84 [12893368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84 [12902540.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]
  • (PMID = 17071602.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; EC 3.1.- / Endoribonucleases; EC 3.1.26.3 / DICER1 protein, human; EC 3.1.26.3 / Ribonuclease III; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Other-IDs] NLM/ PMC1780192
  •  go-up   go-down


96. Pérez López ME, García Mata J, García Gómez J, Salgado Fernández M, Fírvida Pérez JL: [Prostate adenocarcinoma and synchcronous multiple myeloma: a case report]. Actas Urol Esp; 2007 Feb;31(2):157-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate adenocarcinoma and synchcronous multiple myeloma: a case report].
  • [Transliterated title] Adenocarcinoma prostático y mieloma múltiple sincrónicos: a propósito de un caso.
  • PURPOSE: To report a case of synchronous prostatic cancer with multiple myeloma as inusual neoplasm presentation.
  • To indicate the clinical data that they help to suspect the myeloma presence in the prostate bone metastatic disease.
  • CASE REPORT: Patient 63 years old diagnosed of prostatic carcinoma with bone metastasis and BAC good responsive, who have clinical deterioration, hypercalcemia and renal insufficiency.
  • [MeSH-major] Adenocarcinoma / diagnosis. Multiple Myeloma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Prostatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645096.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


97. Chua CW, Chiu YT, Yuen HF, Chan KW, Wang X, Ling MT, Wong YC: Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma. APMIS; 2010 Dec;118(12):918-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma.
  • One of the common features in advanced prostate cancer is bone metastasis.
  • In this study, we investigated the clinical relevance of a bone factor, MSX2, in predicting the metastatic ability of prostate adenocarcinoma.
  • Evaluation of MSX2 expression was performed using prostate cell lines as well as patient specimens.
  • A sharp decrease in MSX2 was found in primary prostate cancer cells, 22Rv1, when compared with the non-malignant counterparts, followed by a gradual increase in more aggressive prostate cancer cell lines.
  • Interestingly, the MSX2 protein was upregulated and predominantly expressed in the nucleus in aggressive prostate cancer cell line, C4-2b, compared with the less aggressive 22Rv1.
  • Consistent with the in vitro results, MSX2 nuclear expression was significantly higher in nodular hyperplasia when compared with high-grade prostatic intraepithelial neoplasia (PIN), while MSX2 nuclear expression in prostate adenocarcinoma was higher than that in high-grade PIN.
  • Taken together, MSX2 may serve as a potential biomarker in predicting primary prostate tumors with higher metastatic capability.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 APMIS.
  • (PMID = 21091772.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MSX2 protein
  •  go-up   go-down


98. Sciarra A, Lichtner M, Autran GA, Mastroianni C, Rossi R, Mengoni F, Cristini C, Gentilucci A, Vullo V, Di Silverio F: Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate; 2007 Jan 1;67(1):1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients.
  • PURPOSE: We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count.
  • METHODS: Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease.
  • RESULTS: We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002).
  • CONCLUSIONS: We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Dendritic Cells / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17075798.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Altinok G, Powell IJ, Che M, Hormont K, Sarkar FH, Sakr WA, Grignon D, Liao DJ: Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma. Prostate Cancer Prostatic Dis; 2006;9(1):77-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma.
  • The present study is the first report on immunohistochemical data of QM in human prostatic tissues.
  • Paraffin sections of human prostate cancer samples were immunohistochemically stained for QM.
  • QM protein expression was found in all normal prostate glands adjacent to prostate cancer and in various intraepithelial neoplasia (PIN).
  • In prostate cancer, the staining intensity and stained areas were decreased, compared to the normal glands and PIN lesions; in high-grade tumors only some patches of tumor cells showed positivity.
  • Moreover, staining in prostatic adenocarcinoma was often topographically patchy and varied from negative or weak (1+) to intense (3+).
  • This preliminary study suggests that decreased QM expression may be associated with early development of prostate cancer, but later a high level of QM may facilitate progression of the tumors to a more aggressive phenotype.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism. Ribosomal Proteins / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331298.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ribosomal Proteins; 0 / Tumor Suppressor Proteins; 0 / ribosomal protein L10
  •  go-up   go-down


100. Klock C, Gomes R, João M, Netto G: Prostate melanosis associated with acinar adenocarcinoma. Int J Surg Pathol; 2010 Oct;18(5):379-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate melanosis associated with acinar adenocarcinoma.
  • Prostate melanosis is an uncommon lesion of uncertain etiology where melanin deposition is seen in the epithelium, in the stroma, or in the form of a blue nevus.
  • There are three reports in the literature of melanosis seen in association with prostatic adenocarcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Melanosis / pathology. Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098014.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down






Advertisement